Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

BIOCOMPATIBLE ULTRASONIC COUPLING AGENT FOR ENDOSCOPE AND USE THEREOF

Disclosed herein is a biocompatible ultrasonic coupling agent for endoscopes, comprising a biocompatible modified starch and a pharmaceutically acceptable carrier, or comprising an ingredient selected from the group consisting of cellulose, polyvinylpyrrolidone, polyoxyethylene, sodium alginate, glucan, hyaluronic acid, chitosan, light sensitive glue, ultrasonic sensitive glue, pH sensitive glue, gelatin and carbomer, and a pharmaceutically acceptable carrier; wherein the ultrasonic coupling agent produces an acoustic characteristic impedance matching the acoustic characteristic impedance of the human tissues during use for endoscopic ultrasound examination. Disclosed herein is also a kit for endoscopic ultrasound examination, comprising the said biocompatible ultrasonic coupling agent. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. A method of using an ultrasonic coupling agent during an endoscopic ultrasound examination , comprising:acquiring the ultrasonic coupling agent wherein the ultrasonic coupling agent comprises a biocompatible modified starch, wherein the biocompatible modified starch comprises at least one of pre-gelatinized starches, acid-modified starches, composite modified starches, esterified starches, etherified starches, cross-linked starches, or graft starches and wherein the biocompatible modified starch has a molecular weight from 3,000 to 2,000,000 Dalton, has a water absorbency capability from 2 to 100 times of its own weight, and has a particle size ranging from 1 to 1000 μm; andapplying the ultrasonic coupling agent proximate human tissue during the endoscopic ultrasound examination, wherein the biocompatible modified starch is adapted to produces an acoustic characteristic impedance matching an acoustic characteristic impedance of the human tissues.11. The method of claim 10 , wherein the biocompatible modified starch has a molecular weight in a range of 3 claim 10 , ...

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 153-. (canceled)54. An anti-adhesion product in the form of a film , plaster , or sponge , said product comprising a biocompatible modified starch , wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units contained in the starch , wherein the product forms an adhesion barrier in the form of a starch-blood coagulation matrix upon contacting a wound tissue.55. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch particles exhibit a water absorbency capacity that is at least 1 times its own weight.56. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch particles exhibit a water absorbency capacity that is 2-500 times its own weight.57. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch exhibits a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C.58. The anti-adhesion product of claim 54 , wherein the biocompatible modified starch is degradable by amylase.59. The anti-adhesion product of claim 54 , wherein the ...

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Method for preventing and controlling apolygus lucorum in tea garden by means of insect-proof net

The invention relates to a method for preventing and controlling apolygus lucorum in a tea garden by means of an insect-proof net. The method comprises the following steps of preparing the insect-proof net; determining the time when apolygus lucorum adults move back to the tea garden by a net sweeping method; and covering the insect-proof net. According to the method, a test for preventing and controlling the apolygus lucorum in the tea garden by means of a method for covering the insect-proof net is performed for the first time in the country, the time when the apolygus lucorum adults move back is determined by the net sweeping method from 20th, September to 10th, October every year by aiming at the propagation regularity of the apolygus lucorum, and the net is covered in time, so that the effects of prevention and control are good, the influence on the growth of tea leaves is small, and the method has important significance in the aspects of reducing pesticide residues in the tea leaves ...

OPTICAL IMAGING LENS ASSEMBLY

Embodiments of the present disclosure provide an optical imaging lens assembly that comprising, sequentially from an object side to an image side of the optical imaging lens assembly along an optical axis: a first lens having a negative refractive power, an object side surface of the first lens is convex surface and an image side surface of the first lens is a concave surface; a stop; a second lens having a positive refractive power, an object side surface of the second lens is a concave surface and an image side surface of the second lens is a convex surface; a third lens having a refractive power; a fourth lens having a refractive power, an object side surface of the fourth lens is a concave surface and an image side surface of the fourth lens is a convex surface. A relative illuminance RI corresponding to a maximal field-of-view of the optical imaging lens assembly satisfies: RI≥50%; and at least one of the first lens to the fifth lens is a lens made of plastic material.

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 128-. (canceled)29. A hemostatic powder comprising a hemostatic material , wherein the hemostatic material consists of biocompatible modified starch particles , wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units in the starch , wherein the biocompatible modified starch particles are non-porous and substantially devoid of a microporous surface , wherein the powder has an adhesiveness sufficient to form a starch-blood coagulation matrix upon contacting a wound tissue.30. The hemostatic powder of claim 29 , wherein the biocompatible modified starch exhibits a water absorbency capacity that is at least 1 times its own weight.31. The hemostatic powder of claim 29 , wherein the biocompatible modified starch exhibits a water absorbency capacity that is 2-500 times its own weight.32. The hemostatic powder of claim 29 , wherein the biocompatible modified starch exhibits a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C.33. The hemostatic powder of claim 29 , wherein the hemostatic powder is ...

Composition for submucosal injection, reagent combination, and applications thereof

Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 μm. The viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection.

Processing method for communication terminal to send messages

The invention discloses a processing method for a communication terminal to send messages. The method includes the following steps: arranging at least one kind of popular phrases and symbols of a specific character and completing an association setting of the specific character; editing a content of a short message, selecting a pending character and calling the association setting which is corresponding to the pending character; adding the association setting which is corresponding to the pending character to the content of the short message so as to obtain the short message to be sent. In the invention, through the pre-established association setting of the popular phrases and/or symbols of the specific character, wonderfulness and diversification of the content can be realized according to input character information which brings great convenience for users to edit the message.

Processing technology for cold and hot smoking of sturgeon meat

The invention relates to the technical field of food processing, in particular to a processing technology for cold and hot smoking of sturgeon meat, and provides a process for smoking the sturgeon meat. After the sturgeon meat is subjected to pre-treatment, removal of spines and peritoneum, slicing, pickling, dyeing, draining, cold smoking or hot smoking, temporary freezing, slicing and packaging, quick-freezing, metal detection and the like. The smoked product is flavored but not greasy, tastes good, is low in content of cholesterol and long in shelf life, and has an attractive color and strong and durable fragrance. By the process provided by the invention, nutrient ingredients of fishes are not damaged, the process is convenient to implement, and the production cycle is short.

Biocompatible hemostatic product and preparation method thereof

Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 μm to 2000 μm and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Wood adhesives containing reinforced additives for structural engineering products

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Complex system transfer function computing method based on high-precision polynomial arithmetic

The invention belongs to the technical field of carrier rocket control, and particularly relates to a complex system transfer function computing method based on the high-precision polynomial arithmetic. The method comprises the first step of pre-processing input data, the second step of calculating a state space matrix, the third step of calculating the transfer function of a rocket body by adopting the FADEEVA method, the fourth step of expanding floating point data information to obtain the transfer function of the sum of the rocket body, a platform and a gyroscope and the transfer function of the sum of the rocket body, the platform, the gyroscope and a steering engine, and the fifth step of obtaining the transfer function of an attitude control system open loop. The limitation of the word length of a robot is broken through, effective figures are reserved, the computing round-off error is reduced, and the solving precision of the transfer function is improved in the process of processing ...

NANO-IMPRINTING TEMPLATE, SYSTEM, AND IMPRINTING METHOD

A nano-imprinting template, a system, and an imprinting method are provided. The nano-imprinting template () comprises: a first baseplate () transparent to ultraviolet light; an imprinting pattern structure () formed on the first surface of the first baseplate (); a heating element () formed on the second surface, opposite to the first surface, of the first baseplate (), wherein the heating element () is transparent to ultraviolet light; and a first electrode pair () formed on the second surface and used for supplying a current applied by an external power supply to the heating element () so as to make the heating part () generate heat. The nano-imprinting template () and the system seamlessly integrate an ultraviolet curing nano-imprinting technology with a thermoplastic nano-imprinting technology, which have the advantages of small size of equipment, low cost, simple process and the like. When the template and the system are used to carry out thermoplastic nano-imprinting, a large area of micro-nano patterns can be copied. In addition, when the template and the system are used to carry out UV curing nano-imprinting, the purposes of improving the process throughput and reducing the pattern replication defects are achieved. 1. A nano-imprinting template , comprising:a first baseplate transparent to ultraviolet light;an imprinting pattern structure, formed on a first surface of the first baseplate;a heating element, formed on a second surface of the first baseplate opposite to the first surface, wherein the heating element is transparent to ultraviolet light; anda first electrode pair, formed on the second surface, and used for supplying a current provided by an external power supply to the heating element so as to make the heating element generate heat.2. The nano-imprinting template according to claim 1 , characterized in that the heating element is arranged in such a way that the first baseplate is uniformly heated.3. The nano-imprinting template according to ...

Wood Adhesives Containing Reinforced Additives for Structural Engineering Products

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 1. A method of effecting hemostasis in a wounded tissue of an animal , comprising: applying , directly onto the wounded tissue of the animal , a powder that comprises biocompatible modified starch particles , such that the applied powder forms a starch-blood coagulation matrix upon contacting the wounded tissue , thereby effecting homeostasis.2. The method of claim 1 , wherein the biocompatible modified starch particles have a grain diameter of 1 to 1000 μm.3. The method of claim 1 , wherein the biocompatible modified starch particles have a molecular weight of 15 claim 1 ,000 daltons or more.4. The method of claim 1 , wherein the biocompatible modified starch particles exhibit water absorbency capacity of at least 1 times its own weight.5. The method of claim 1 , wherein the biocompatible modified starch particles exhibit water absorbency capacity of 2-500 times its own weight preferably.6. The method of claim 1 , wherein the biocompatible modified starch particles exhibit a viscosity of a 6.67% water suspension not lower than 30 mPas under 37° C.7. The ...

BIOCOMPATIBLE HEMOSTATIC PRODUCT AND PREPARATION METHOD THEREOF

Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 μm to 2000 μm and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. A method of using a biocompatible hemostatic product to treat a wound within a body cavity of a patient , comprising applying an amount of the biocompatible hemostatic product to said wound , wherein the biocompatible hemostatic product comprises polyethylene oxide particles and wherein said amount is sufficient to cause at least one of hemostasis in said wound , sealing said wound , reducing exudation of said wound , promoting tissue healing around said wound , protecting a surface of said wound , and avoiding infection of said wound.26. The method of wherein the wound is located in at least one of the patient's respiratory tract claim 25 , digestive tract claim 25 , genital tract claim 25 , and gastrointestinal tract.27. The method of wherein the polyethylene oxide particles have a viscosity-average molecular weight ranging from 100 claim 25 ,000 to 7 claim 25 ,000 claim 25 ,000 Daltons.28. The method of wherein the polyethylene oxide particles have a particle size ranging ...

Pump port structure

The invention provides a pump port structure, which belongs to a water pump accessory in mechanical equipment. The pump port structure comprises a flange, a sealing member, a spacer sleeve and a port ring, wherein a sealing region is formed between the flange and the spacer sleeve; the gap between the port ring and a pump body impeller is 0.025-0.1 mm; and the gap between the spacer sleeve and a pump shaft is 0.025-0.1 mm. According to the pump port structure provided by the invention, the water return quantity at the position of the port ring is greatly reduced, the power loss is reduced, and the pump port structure has both the features and the functions of sliding bearing type structures.

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Massage ball

Wood adhesives containing reinforced additives for structural engineering products

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Modified starch material of biocompatible hemostasis

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Modified Starch Material of Biocompatible Hemostasis

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 1. A biocompatible modified starch , which is a pre-gelatinized starch product having water absorbency capacity not lower than 1 time its own particle weight.2. The biocompatible modified starch claim 1 , as recited in claim 1 , which is used for hemostasis claim 1 , adhesion prevention claim 1 , tissue healing promotion claim 1 , wound sealing claim 1 , and wounded tissue bonding in surgical operation and trauma treatment.3. The biocompatible modified starch claim 2 , as recited in claim 2 , which has a molecular weight 10 claim 2 ,000-2 claim 2 ,000 claim 2 ,000 Daltons or more and a grain diameter of 10 to 1000 μm.4. The biocompatible modified starch claim 3 , as recited in claim 3 , wherein the starch product is in form of hemostatic powder which has starch grains with grain diameter of 30˜500 μm claim 3 , wherein at least 95% starch grains in said hemostatic powder with a diameter of 30˜500 μm in total.5. The biocompatible modified starch claim 2 , as recited in claim 2 , which contains one or more groups of pre-gelatinized starch claim 2 , ...

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

SYSTEM AND METHOD FOR MICRO-NANO MACHINING BY FEMTOSECOND LASTER TWO-PHOTON POLYMERIZATION

Disclosed are a system and method for micro-nano machining by femtosecond laser two-photon polymerization. The system includes: a femtosecond laser, an external light path modulation unit, an image capture apparatus, a focusing lens, a displacement platform, a computer and a monitoring apparatus, where the image capture apparatus is configured to capture cross-section graphs of a three-dimensional micro-nano device layer by layer, so that modulated femtosecond lasers form parallel beams arranged according to all layers of the cross-section graphs.

Real-time monitoring system of transformer substation

The invention discloses a real-time monitoring system of a transformer substation. The real-time monitoring system comprises a control computer, a video monitoring device, a ZigBee wireless gateway and an alarm host, wherein both the video monitoring device and the alarm host are connected with the control computer, the ZigBee wireless gateway is connected with the alarm host, the ZigBee wireless gateway is connected with a temperature and humidity sensor, a sulfur hexafluoride monitoring sensor, a water leakage detection sensor, an air conditioner controller, a dehumidifier controller and a draught fan controller through a ZigBee wireless communication network, and the temperature and humidity sensor, the sulfur hexafluoride monitoring sensor, the water leakage detection sensor, the air conditioner controller, the dehumidifier controller and the draught fan controller transmit the detected data to the alarm host through the ZigBee wireless communication network and the ZigBee wireless ...

Grease specially used for moon cakes, and preparation method thereof

The invention discloses grease specially used for moon cakes, and a preparation method of the grease. Soybean oil and palm stearin are selected as oil base by scientifically compounding an oil material; the grease which is specially used for the moon cakes and is produced by blending, quenching, kneading and curing through a flow state shortening production technology is low in trans fatty acid content and is rich in human body essential fatty acid linoleic acid and linolenic acid; the grease specially used for the moon cakes is in a flow state at the room temperature; the solid fat in the flow state grease is even in distribution and smaller in change along with the temperature; the grease specially used for the moon cakes is wider in adjustable temperature range and easy to operate and use; the moon cakes made by the special grease are even and stable in oil return.

SCALABLE AND REDUNDANT MINI-INVERTERS

The Scalable and Redundant Mini-inverters as described in this invention include double, triple, or quadruple redundant capabilities so that the Mini-inverters can work in a harsh environment for a prolonged period of time. A number of regular, redundant, triple redundant, or quadruple redundant Mini-inverters with one, two, three, or multiple input channels in a mixed variety can easily connect to one, two, three, or multiple DC power sources such as solar PV modules, invert the DC power to AC power, and daisy chain together to generate AC power to the power grid. 1. A system for providing AC power to a power grid from a plurality of individual DC power sources each having a DC power output port , comprising:a) a plurality of power inverters, each of said power inverters being connected to one DC power source, and having an AC power input port and an AC power output port;b) said AC power output port of each inverter being connected in a daisy chain to the AC power input port of the next inverter, except for the AC power input port of the first inverter being left open, and the AC power output port of the last inverter being connected to a power service panel of the power grid; i) a main DC-DC boost converter arranged to convert the voltage of said DC power source to a higher DC voltage suitable for inversion;', 'ii) a backup DC-DC boost converter arranged to convert the voltage of said DC power source to a higher DC voltage suitable for inversion;', 'iii) a DC input channel selector constructed and arranged to connect the main DC-DC boost converter to said DC power source when the main DC-DC boost converter is working and connect the backup DC-DC boost converter to the DC power source when the main DC-DC boost converter is not working;', 'iv) a DC power combiner connected to said main DC-DC boost converter and said backup DC-DC boost converter;', 'v) a DC-AC inverter connected to said DC power combiner and arranged to invert the DC power to AC power with voltage ...

Compositions And Methods Involving Respiratory Syncytial Virus Subgroup B Strain 9320

The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described. 139-. (canceled)40. A method for stimulating the immune system of an individual to produce a protective immune response against respiratory syncytial virus , the method comprising administering to the individual an immunologically effective amount of the recombinant respiratory syncytial virus in a physiologically acceptable carrier , wherein said recombinant respiratory syncytial virus comprises an isolated or recombinant nucleic acid comprising a polynucleotide sequence selected from the group consisting of:(a) SEQ ID NO:1 or a complementary polynucleotide sequence thereof;(b) a polynucleotide sequence that is greater than 97.8% identical to SEQ ID NO:1 or a complementary polynucleotide sequence thereof, as determined by BLASTN using default parameters;(c) a polynucleotide sequence that hybridizes under stringent conditions over substantially the entire length of a polynucleotide subsequence comprising at least 100 contiguous nucleotides of SEQ ID NO: 1 or a complementary polynucleotide sequence thereof, wherein the polynucleotide sequence hybridizes to the polynucleotide subsequence of SEQ ID NO: 1 or the complementary polynucleotide sequence thereof under said stringent conditions with at least 2× a signal to noise ratio that the polynucleotide sequence hybridizes to a corresponding polynucleotide subsequence of SEQ ID NO: 13 or a complementary polynucleotide sequence thereof;(d) a polynucleotide sequence comprising at least one unique polynucleotide subsequence ...

SMART AND SCALABLE OFF-GRID MINI-INVERTERS

A method and apparatus is disclosed for intelligently inverting DC power from DC sources such as photovoltaic (PV) solar modules to single-phase or three-phase AC power to supply power for off-grid applications. A number of regular or redundant off-grid Mini-Inverters with one, two, three, or multiple input channels in a mixed variety can easily connect to one, two, three, or multiple DC power sources such as solar PV modules, invert the DC power to AC power, and daisy chain together to generate and supply AC power to electrical devices that are not connected to the power grid including motors, pumps, fans, lights, appliances, and homes. 1. A system for providing AC power to an AC load from a plurality of individual DC power sources each having a DC power output port , comprising:a) a plurality of power inverters, each of said power inverters having one DC power input port, an AC power input port, and an AC power output port;b) said AC power output port of each inverter being connected in a daisy chain to the AC power input port of the next inverter, except for the AC power input port of the first inverter being left open, and the AC power output port of the last inverter being connected to the AC load; i) a DC-DC boost converter arranged to convert the voltage of a DC power source to a higher DC voltage suitable for inversion;', 'ii) a DC-AC inverter connected to said DC-DC boost converter and arranged to invert the DC power to AC power;', 'iii) an internal AC powerline that allows the generated AC power to be sent to the AC load through an external AC powerline;', "iv) a load interface circuit connected to said DC-AC inverter and to said internal AC powerline, said load interface circuit being arranged to filter high-frequency components out of the said DC-AC inverter's AC output;", 'v) a digital microcontroller connected to said DC-DC boost converter, DC-AC inverter, and load interface circuit, said microcontroller arranged to monitor the DC boost voltage, ...

Enclosure and Message System of Smart and Scalable Power Inverters

An enclosure design is disclosed to accommodate and support the unique features and capabilities of the Smart and Scalable Power Inverters or Mini-Inverters that have multiple input channels to easily connect to multiple solar PV panels, invert the DC power to AC power, and daisy chain together to generate AC power to feed the power grid or supply power to electrical devices. Further disclosed is a message system using LEDs (light-emitting diodes) mounted on the enclosure to indicate the system status and the status of each input channel of the Smart and Scalable Mini-Inverters. 1. A multiple channel power inverter , comprising:a) at least two DC power input channels;b) an AC power output port arranged to supply AC power to the AC power grid;c) for each DC power input channel, a DC-DC boost converter arranged to convert the voltage of a DC power source to a higher DC voltage suitable for inversion;d) a DC power combiner connected to said DC-DC boost converters for combining the DC output from all DC-DC boost converters and allowing the said DC-DC boost converters to connect in parallel so that all DC currents are added together;e) a DC-AC inverter connected to said DC power combiner and, arranged to invert the DC power to AC power;f) an internal AC powerline that combines the generated AC power with the external AC power from the power grid;g) a load interface circuit connected to said DC-AC inverter and to said internal AC powerline, said load interface circuit being arranged to filter high-frequency components out of the said DC-AC inverter's AC output;h) a digital microcontroller connected to said DC-DC boost converter, DC-AC inverter, and load interface circuit, said microcontroller arranged to monitor the DC boost voltage, control the DC-DC boost converter, perform maximum power point tracking (MPPT), perform DC-AC inversion and AC power synchronization, monitor AC current and voltage for generated power amount and status, perform powerline communications, and ...

Digital Microfluidic Platform for Actuating and Heating Individual Liquid Droplets

A digital microfluidic platform utilizes dual active matrix circuitry to actuate and heat liquid droplets on a biochip. Liquid droplets are introduced into a droplet handling area of the biochip where they can be actuated by electrodes residing in pixels of an actuating active matrix array according to the electrowetting on dielectric phenomenon and heated by heating elements residing in pixels of a heating active matrix array. Pixels of the actuating active matrix array and the heating active matrix array are independently addressable such that droplets in the droplet handling area can be selectively heated and actuated according to their location. The actuating active matrix array and heating active matrix array can be formed on the same or different substrates with the droplet handling area disposed above or between the substrates. 1. A device for manipulating droplets of fluid , comprising: a first switch coupled to an electrode, wherein each first switch is controllable to move a droplet with respect to its associated electrode; and', 'a second switch coupled to a heating element, wherein each second switch is controllable to heat a droplet proximate to its associated heating element;, 'a first substrate comprising a plurality of pixels arranged in rows and columns, each pixel comprisinga second substrate; anda droplet handling area disposed between the first substrate and the second substrate, wherein the droplet handling area comprises at least one fluid input port for introducing a droplet into the droplet handling area, and at least one fluid output port for removing a droplet from the droplet handling area.2. The device of claim 1 , wherein the droplet handling area further comprises at least one spacer between the first and second substrates.3. The device of claim 1 , further comprising a hydrophobic layer between the first substrate and the droplet handling area.4. The device of claim 1 , further comprising a first row and a first column coupled to each ...

ARRANGEMENT AND METHOD FOR AUTOMATICALLY DETERMINED TIME CONSTANT FOR A CONTROL DEVICE

A method includes a step of obtaining in a processing circuit a sequence of elements between a first device and a supply air temperature sensor of an air handling unit. The processing circuit also obtains an estimate for time constants associated with each element of the sequence. The processing circuit adds the time constants to obtain a process time constant estimate. The method further includes controlling a device based at least in part on the process time constant estimate. 1. A method comprising:a) obtaining in a processing circuit a sequence of elements between a first device and a supply air temperature sensor of an air handling unit;b) obtaining in the processing circuit an estimate for time constants associated with each element of the sequence;c) adding in the processing circuit the time constants to obtain a process time constant estimate; andd) controlling a device based at least in part on the process time constant estimate.2. The method of claim 1 , wherein the sequence of elements includes at least one coil and step b) further comprises generating claim 1 , using the processing circuit claim 1 , a time constant estimate for the coil based on quantifiable physical characteristics of the coil.3. The method of claim 2 , wherein step b) further comprises generating the time constant estimate of the coil using a maximum liquid flow rate through the coil.4. The method of claim 3 , wherein step b) further comprises generating the time constant estimate of the coil using a maximum air flow rate past the coil.5. The method of claim 3 , wherein b) further comprises generating the time constant estimate of the coil as the value K (F/F) claim 3 , wherein K is a constant claim 3 , Fis the maximum air flow rate past the coil and Fis the maximum liquid flow rate through the coil.6. The method of claim 5 , wherein step a) further comprises obtaining a constant value for a time constant of the first device if the first device is an actuator claim 5 , the time ...

Model-Free Adaptive Control of Supercritical Circulating Fluidized-Bed Boilers

A novel 3-Input-3-Output (3×3) Fuel-Air Ratio Model-Free Adaptive (MFA) controller is introduced, which can effectively control key process variables including Bed Temperature, Excess O2, and Furnace Negative Pressure of combustion processes of advanced boilers. A novel 7-input-7-output (7×7) MFA control system is also described for controlling a combined 3-Input-3-Output (3×3) process of Boiler-Turbine-Generator (BTG) units and a 5×5 CFB combustion process of advanced boilers. Those boilers include Circulating Fluidized-Bed (CFB) Boilers and Once-Through Supercritical Circulating Fluidized-Bed (OTSC CFB) Boilers.

Influenza hemagglutinin and neuraminidase variants

Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.

Model-Free Adaptive (MFA) Control with Intelligent Engine and Loop Inspection

A method and apparatus for intelligently controlling continuous process variables. An automatic controller comprises an Intelligent Engine mechanism and a number of Model-Free Adaptive (MFA) controllers, each of which is suitable to control a process with specific behaviors. The Intelligent Engine can automatically select the appropriate MFA controller and its parameters so that the automatic controller can be easily used by people with limited control experience and those who do not have the time to commission, tune, and maintain automatic controllers. 2. The controller of claim 1 , in which said control signal u(t) is the sum of said denormalized value and the value Ke(t).5. A method of inspecting the functionality of a control system using automatically selected Model-Free Adaptive (MFA) controllers claim 1 , comprising:a) establishing a database to save the selected MFA controller and related configuration information of that controller;b) checking all configuration information and inputting any necessary changes;c) if all configurations are accurate, individually verifying that the control loop signals of setpoint (SP), process variable (PV), controller output (OP), and output tracking variable (OTV) are correct, and that the controller is in manual mode; andd) if all of said signals are verified to be correct, indicating to the user that the control system is ready to launch.6. The method of claim 5 , in which the Model-Free Adaptive (MFA) controller is a general-purpose controller including a P (proportional) controller claim 5 , a PI (proportional-integral) controller claim 5 , a PD (proportional-derivative) controller claim 5 , and a PID (proportional-integral-derivative) controller. This application is a divisional of U.S. application Ser. No. 12/853,832, filed on Aug. 10, 2010, which is herein incorporated by reference.This invention was made with government support under SBIR grant DE-FG02-08ER84944 awarded by the U.S. Department of Energy. The ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen or —(C-Calkyl)C(O)NRR.3. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.4. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.8. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.9. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt or stereoisomer thereof.10. The method of claim 9 , wherein the disease or condition is cancer claim 9 , stroke claim 9 , diabetes claim 9 , hepatomegaly claim 9 , cardiovascular disease claim 9 , multiple sclerosis claim 9 , Alzheimer's disease claim 9 , cystic fibrosis claim 9 , viral disease claim 9 , autoimmune diseases claim 9 , atherosclerosis claim 9 , restenosis claim 9 , psoriasis claim 9 , rheumatoid arthritis claim 9 , inflammatory bowel disease claim 9 , asthma claim 9 , allergic disorders claim 9 , inflammation claim 9 , neurological disorders claim 9 , a hormone-related disease claim 9 , conditions associated with organ transplantation (e.g. claim 9 , transplant rejection) claim 9 , immunodeficiency disorders claim 9 , ...

METASURFACE PRIMARY LENS AND METASURFACE SECONDARY LENS, MANUFACTURING METHOD THEREOF, AND OPTICAL SYSTEM

Provided are a metasurface primary mirror, a metasurface secondary mirror, a method for manufacturing a metasurface primary mirror, a method for manufacturing a metasurface secondary mirror, and an optical system. The metasurface primary mirror, manufactured by using the method for manufacturing a metasurface primary mirror, includes a transparent substrate which includes a primary mirror metasurface pattern on the transparent substrate. The primary mirror metasurface is configured to satisfy a primary mirror phase distribution such that incident light reflected by a metasurface secondary mirror onto the metasurface primary mirror is reflected and focused. 1. A method for manufacturing a metasurface primary mirror , comprising:providing a transparent substrate; andforming, on the transparent substrate, a primary mirror metasurface functional unit pattern satisfying a primary mirror phase distribution such that incident light reflected by a metasurface secondary mirror onto the primary mirror is reflected and focused.2. The method for manufacturing a metasurface primary mirror of claim 1 , wherein the primary mirror phase distribution is determined according to a set parameter combined with ray optics and a general law of reflection claim 1 , and the set parameter comprises a focal length of a system claim 1 , an aperture of the metasurface primary mirror claim 1 , an aperture of the metasurface secondary mirror claim 1 , a distance between the metasurface primary mirror and the metasurface secondary mirror claim 1 , an operating wavelength of the system claim 1 , and a mapping relationship between a position where incident light arrives on the metasurface secondary mirror and a position where the incident light reflected by the metasurface secondary mirror arrives on the metasurface primary mirror; orthe primary mirror phase distribution is determined according to a geometric shape of a curved primary mirror in a set curved reflective objective, wherein the curved ...

MODIFIED STARCH MATERIAL OF BIOCOMPATIBLE HEMOSTASIS

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 128-. (canceled)29. A method of reducing adhesion between a wounded tissue and an other tissue of an animal , comprising: applying , directly onto the wounded tissue of the animal , a powder consisting essentially of biocompatible modified starch particles and optionally an antibiotic , such that the applied powder forms an adhesion barrier , thereby reducing adhesion between the wounded tissue and the other tissue.30. The method of claim 29 , wherein the biocompatible modified starch particles have a grain diameter of 1 to 1000 μm.31. The method of claim 29 , wherein the biocompatible modified starch particles have a molecular weight of 15 claim 29 ,000 daltons or more.32. The method of claim 29 , wherein the biocompatible modified starch particles exhibit water absorbency capacity of at least 1 times its own weight.33. The method of claim 29 , wherein the biocompatible modified starch particles exhibit water absorbency capacity of 2-500 times its own weight.34. The method of claim 29 , wherein the biocompatible modified starch particles exhibit a ...

Self-Organizing Sensing and Actuation for Automatic Control

A Self-Organizing Process Control Architecture is introduced with a Sensing Layer, Control Layer, Actuation Layer, Process Layer, as well as Self-Organizing Sensors (SOS) and Self-Organizing Actuators (SOA). A Self-Organizing Sensor for a process variable with one or multiple input variables is disclosed. An artificial neural network (ANN) based dynamic modeling mechanism as part of the Self-Organizing Sensor is described. As a case example, a Self-Organizing Soft-Sensor for CFB Boiler Bed Height is presented. Also provided is a method to develop a Self-Organizing Sensor. 1. A self-organizing process control system , comprising:a) a control layer that includes one or multiple automatic controllers for controlling various process variables;b) a sensing layer that includes one or multiple sensors for measuring various process variables;c) an actuation layer that includes one or multiple actuators that take control command signals from the controllers and manipulate certain process inputs or manipulated variables;d) a process layer that includes physical processes or systems with inputs and outputs that have dynamic relationships; ande) one or more of a self-organizing sensor (SOS) and a self-organizing actuator (SOA).2. The control system of claim 1 , in which e) comprises self-organizing sensors (SOS) having parallel and distributed information processing capabilities.3. The control system of claim 1 , in which e) comprises self-organizing actuators (SOA) having parallel and distributed information processing capabilities.4. The control system of claim 1 , comprising a self-organizing sensor (SOS) characterized by one or more of:a) having one or multiple inputs from the process layer;b) having one or multiple inputs from the sensing layer;c) sending its output to the sensing layer; andd) sending its output to the control layer.5. The control system of claim 1 , comprising a self-organizing actuator (SOA) characterized by one or more of:a) taking commands from the ...

EXPANSION POLYMERIZATION IMPRINTING GLUE FOR NANO-PRINTING

An expansion polymerization imprinting glue for nano-imprinting. Raw materials required for the preparation of the expansion polymerization imprinting glue comprise a low polymer and an expansion monomer. Compared with the prior art, after the expansion monomer is introduced into the expansion polymerization imprinting glue for nano-imprinting, the expansion monomer can be polymerized with the low polymer, the volume change of the imprinting glue after polymerization can be adjusted, and accordingly the volume shrinkage after the imprinting glue is cured is reduced or even eliminated; and the imprinting glue having zero curing shrinkage or volume expansion can be obtained by adjusting the content of the expansion monomer. The imprinting glue can effectively reduce the residual stress in a micro-nano pattern, and the generation of pattern defects in the nano-imprinting demolding process caused by the residual stress is reduced while accurate pattern copying is implemented. 1. An expansion polymerization imprint resist for nano-imprinting , raw materials required for the preparation of which comprise an oligomer , wherein the raw materials further comprise an expansion monomer.2. The expansion polymerization imprint resist for nano-imprinting according to claim 1 , wherein the expansion monomer accounts for 10-200% of the weight of the oligomer.3. The expansion polymerization imprint resist for nano-imprinting according to claim 1 , wherein the expansion monomer is one selected from the group consisting of spiro orthoester compound claim 1 , spiro orthocarbonate compound claim 1 , bicyclic orthoester compound and bicyclic lactone compound claim 1 , or a mixture of at least two thereof.8. The expansion polymerization imprint resist for nano-imprinting according to claim 1 , wherein the raw materials further comprise a photoinitiator claim 1 , which accounts for 0.1-5% of the total weight of the oligomer and the expansion monomer.9. The expansion polymerization imprint ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen or —(C-Calkyl)C(O)NRR.3. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.4. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.8. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.9. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt or stereoisomer thereof.10. The method of claim 9 , wherein the disease or condition is cancer claim 9 , stroke claim 9 , diabetes claim 9 , hepatomegaly claim 9 , cardiovascular disease claim 9 , multiple sclerosis claim 9 , Alzheimer's disease claim 9 , cystic fibrosis claim 9 , viral disease claim 9 , autoimmune diseases claim 9 , atherosclerosis claim 9 , restenosis claim 9 , psoriasis claim 9 , rheumatoid arthritis claim 9 , inflammatory bowel disease claim 9 , asthma claim 9 , allergic disorders claim 9 , inflammation claim 9 , neurological disorders claim 9 , a hormone-related disease claim 9 , conditions associated with organ transplantation (e.g. claim 9 , transplant rejection) claim 9 , immunodeficiency disorders claim 9 , ...

THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (I): 2. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CH.3. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CN.9. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris cyclopropylcarbonylamino.14. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': c', 'x, 'sub': 1', '6, 'Ris C-Calkyl that is substituted with R; and'}{'sup': x', 'm', 'm', 'n', 'm', 'm', 'm', 'n, 'sub': 1', '6', '1', '6, 'Ris selected from the group consisting of 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl, wherein any 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, or 5-10 membered heteroaryl, wherein any 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with halo, hydroxy, cyano, oxo, —OR, —NRR, —C(O)R, —C(O)OR, —C(O)NRR, or C-Calkyl that is optionally substituted with halo, hydroxy, cyano, oxo or C-Calkoxy.'}21. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.22. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient in need thereof a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.23. The method of claim 22 , wherein the disease or condition is asthma.24. The method of claim 22 , wherein the Janus kinase is JAK1. This application is a continuation of International Application No. PCT/EP2017/060349, filed May 2, ...

TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R, R, R, R, R, Rand Rare defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient. This patent application is a continuation of International Application No. PCT/EP2016/054343, filed Mar. 2, 2016, which claims the benefit under 35 U.S.C. § 119(a) of International Application No. PCT/CN2016/072287, filed Jan. 27, 2016, and claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Appl. No. 62/134,838, filed Mar. 18, 2015, and claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Appl. No. 62/128,234, filed Mar. 4, 2015, each of which is incorporated herein by reference in its entirety.The present invention relates to organic compounds useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of JAK kinases useful for diagnosis and treatment of diseases or conditions responsive to the inhibition of a JAK kinase.Cytokine pathways mediate a broad range of biological functions, including many aspects of inflammation and immunity. Janus kinases (JAK), including JAK1, JAK2, JAK3 and TYK2, are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Cytokine engagement with cognate receptors triggers activation of receptor associated JAKs and this leads to JAK-mediated tyrosine phosphorylation of signal transducer and activator of transcription (STAT) proteins and ultimately transcriptional activation of specific ...

WOOD ADHESIVES CONTAINING REINFORCED ADDITIVES FOR STRUCTURAL ENGINEERING PRODUCTS

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials. 1. A reinforced adhesive comprising an adhesive and an additive material comprising cellulose microfiber only , cellulose fibril aggregates only or cellulose fibril aggregates in combination with nanoclays or microclays , wherein said adhesive is selected from the group consisting of liquid phenolic resins , powdered phenolic resins , polymeric diphenylmethane diisocyanate (pMDI) , amino-based resins (UF) , melamine formaldehyde (MF) , melamine-urea-formaldehyde (MUF) , phenol-urea-formaldehyde (PUF) , melamine-urea-phenol-formaldehyde (MUPF) , phenol-melamine-urea-formaldehyde (PMUF) , protein adhesive , natural phenolic adhesives , epoxy resin , unsaturated polyester and any combination of these.2. The reinforced adhesive according to claim 1 , wherein said adhesive is an adhesive used for the production of composite wood products.3. The reinforced adhesive according to claim 1 , wherein said adhesive is phenol-formaldehyde resin.4. The reinforced adhesive according to claim 1 , wherein said additive material comprises:only cellulose fibril aggregates; or cellulose fibril aggregates in combination with nanoclays and/or microclays.5. The reinforced adhesive according to claim 4 , wherein said cellulose fibril aggregates are selected from cellulose nanofibers claim 4 , macrofibrillated cellulose claim 4 , microcrystalline cellulose claim 4 , bacterial cellulose claim 4 , cellulose whisker claim 4 , cellulose nanotubules claim 4 , cellulose microtubules or are a non-cellulose based nanofiber selected from carbon microfibers claim 4 , carbon nanofibers claim 4 , carbon microtubules claim 4 , carbon nanotubules or combinations ...

GENE CHIP AND METHOD OF PREPARING THE SAME

A gene chip includes a chip carrier, a plurality of DNA nanoballs assembled on the chip carrier, and a polymer film formed on the chip carrier and wrapping the DNA nanoballs. The polymer film includes at least one of a film of a positively charged polymer, a film of a positively charged polymer which is modified, a film of a zwitterionic polymer, and a composite polymer film. The composite polymer film is formed by a layer-by-layer self-assembly process of a positively charged polymer and a negatively charged polymer. The gene chip has good sequencing quality and different functions can be achieved by coating with different polymers, such as the chip surface rapidly drying out and surface non-specific adsorption. A method of preparing a gene chip is further disclosed. 1. A gene chip comprising:a chip carrier;a plurality of DNA nanoballs assembled on the chip carrier; anda polymer film formed on the chip carrier and wrapping the plurality of DNA nanoballs;wherein the polymer film comprises at least one of a film of a positively charged polymer, a film of a positively charged polymer which is modified, a film of a zwitterionic polymer, and a composite polymer film, the composite polymer film is formed by a layer-by-layer self-assembly process of the positively charged polymer and a negatively charged polymer.2. The gene chip of claim 1 , wherein the positively charged polymer comprises at least one of chitosan claim 1 , polylysine claim 1 , polyethyleneimine claim 1 , poly-N claim 1 ,N-dimethylaminoethyl methacrylate claim 1 , and a polymer with pyridyl side groups claim 1 , imidazole salt side groups claim 1 , and quaternary phosphate salt side groups.3. The gene chip of claim 1 , wherein the chip carrier is an aminated silicon wafer.4. A method of preparing a gene chip comprising:placing a chip carrier assembled with DNA nanoballs into a first reaction solution to form a first layer of polymer film covering the DNA nanoballs on the chip carrier, wherein the first ...

Polyester cotton-like yarn-dyed fabric, and manufacturing method and application thereof

Disclosed are a polyester cotton-like yarn-dyed fabric, and a manufacturing method and application thereof. The polyester cotton-like yarn-dyed fabric is interwoven by warp and weft, the warp adopts dyed polyester as a covering layer and low-temperature spandex as a core-spun yarn of a core yarn, a weight ratio of the polyester to the low-temperature spandex is 4-49:1, and the polyester is subjected to alkali deweighting treatment to form an eroded surface. The polyester cotton-like yarn-dyed fabric has good cotton feeling, high elasticity, high color fastness and low ironing shrinkage rate, and is suitable for making high-quality clothing, especially shirts. The manufacturing method of the yarn-dyed fabric is energy-saving and emission-reducing, and can manufacture a novel polyester yarn-dyed fabric with low ironing shrinkage rate, high color fastness and cotton-like hand feeling. Use of the yarn-dyed fabric for making clothing such as shirts increases the selectivity and functionality.

TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF

Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers. 2. The compound of claim 1 , wherein each Ris hydrogen3. The compound of claim 1 , wherein one Ris hydrogen and one Ris methyl.5. The compound of claim 1 , wherein Ris R-substituted or unsubstituted phenyl claim 1 , R-substituted or unsubstituted indazolyl claim 1 , or R-substituted or unsubstituted pyridinyl.68.-. (canceled)9. The compound of claim 1 , wherein each Ris independently halogen claim 1 , NH claim 1 , unsubstituted Calkyl claim 1 , or unsubstituted Chaloalkyl.15. (canceled)16. The compound of claim 1 , wherein Ris L-O-L-R claim 1 , R-substituted or unsubstituted Calkyl claim 1 , or R-substituted or unsubstituted 4-6 membered heterocycle.17. (canceled)18. The compound of claim 16 , wherein Lis a bond and Lis unsubstituted Calkylene.19. (canceled)20. The compound of claim 18 , wherein Ris 4-10 membered heterocycle comprising one N heteroatom.22. (canceled)26. The compound of claim 25 , wherein Ris azetidinyl claim 25 , oxetanyl claim 25 , or thietanedioxide.2728.-. (canceled)29. The compound of claim 1 , wherein Ris hydrogen.3033.-. (canceled)34. The compound of claim 1 , wherein Ris halogen.35. The compound of claim 34 , wherein Ris hydrogen.36. The compound of claim 34 , wherein Ris halogen.37. (canceled)38. The compound of claim 1 , wherein two Rtogether form a bridge between two carbon atoms of ring A claim 1 , wherein the bridge comprises 1-3 carbons.39. (canceled)40. The compound of claim 38 , wherein the bridge comprises 2 carbon atoms.43. (canceled)45. (canceled)4752.-. (canceled)53. The compound of claim 1 , wherein X is NR.54. The compound claim 53 , wherein Ris R-substituted or unsubstituted Calkyl.5559.-. (canceled)60. The compound claim 53 , wherein Ris hydrogen.61. The compound of claim 53 , wherein Ris methyl.62. A compound of Table 1 or Table 2 or a stereoisomer claim 53 , atropisomer claim 53 , tautomer claim 53 , or pharmaceutically acceptable salt ...

MICROFLUIDIC CHIP FOR CIRCULATING TUMOR CELL SEPARATION, CIRCULATING TUMOR CELL SEPARATION METHOD AND COUNTING METHOD

A microfluidic chip for circulating tumor cell separation, comprising a first shell layer, a second shell layer, and a filter membrane between the first shell layer and the second shell layer. A first channel is formed between the filter membrane and the first shell layer; a second channel is formed between the filter membrane and the second shell layer; the first shell layer is provided with m input interfaces and n output interfaces, wherein m is greater than or equal to 1 and n is greater than or equal to 1; the second shell layer is provided with x input interfaces and y output interfaces, wherein x is greater than or equal to 1 and y is greater than or equal to 1. The chip is used for circulating tumor cell separation to achieve high flux, high efficiency, and a simple method, and facilitate promotion. 1. A microfluidic chip for separating circulating tumor cells , comprising a first housing layer , a second housing layer , and a filter membrane disposed between the first housing layer and the second housing layer , wherein a first channel is formed between the filter membrane and the first housing layer , and a second channel is formed between the filter membrane and the second housing layer;the first housing layer is provided with m inlet(s) and n outlet(s), wherein m≥1 and n≥1;the second housing layer is provided with x inlet(s) and y outlet(s), wherein x≥1 and y≥1.2. The microfluidic chip according to claim 1 , wherein the material of the first housing layer comprises any one selected from the group consisting of dimethylsiloxane claim 1 , polymethylmethacrylate claim 1 , or polycarbonate claim 1 , or a combination of at least two selected therefrom.3. The microfluidic chip according to claim 1 , wherein the material of the second housing layer comprises any one selected from the group consisting of dimethylsiloxane claim 1 , polymethylmethacrylate claim 1 , or polycarbonate claim 1 , or a combination of at least two selected therefrom.4. The microfluidic ...

5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein. 12. The compound of claim 1 , wherein Xand Xare independently selected from the group consisting of 3-6-membered cycloalkyl claim 1 , 6-10 membered aryl claim 1 , 5-6 membered heterocycloalkenyl claim 1 , and 5-10 membered heteroaryl claim 1 , wherein each of Xand Xare independently optionally substituted by Y.13. The compound of claim 1 , wherein either Xor Xis a 3-11 membered heterocycloalkyl optionally substituted by Y.14. The compound of claim 1 , wherein Ring Q is (i).15. The compound of claim 1 , wherein tis 0.16. The compound of claim 1 , wherein tis 1.17. The compound of claim 1 , wherein Ring Q is (ii).18. The compound of claim 1 , wherein tis 0.19. The compound of claim 1 , wherein tis 1.20. The compound of claim 1 , wherein R claim 1 , Rand Rare each H.21. The compound of claim 1 , wherein Ris NH.22. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 or 1 claim 1 , and R claim 1 , Rand Rare each H.23. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 1 claim 1 , and Xis NRR claim 1 , wherein Rand Rare each independently H claim 1 , C-Calkyl optionally substituted with 5-6 membered heteroaryl claim 1 , or 3-6 membered cycloalkyl optionally substituted by OH claim 1 , halo claim 1 , CN claim 1 , or C-Calkyl optionally substituted by OH.24. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 claim 1 , and Xis C-Calkyl or 3-6 membered cycloalkyl claim 1 , wherein Xis optionally substituted by —NRR claim 1 , wherein Rand Rare independently H or C-Calkyl.25. The compound of claim 1 , selected from Table 1.26. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.27. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering ...

THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (I): 2. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CH.3. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CN.9. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris cyclopropylcarbonylamino.14. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': c', 'x, 'sub': 1', '6, 'Ris C-Calkyl that is substituted with R; and'}{'sup': x', 'm', 'm', 'n', 'm', 'm', 'm', 'n, 'sub': 1', '6', '1', '6, 'Ris selected from the group consisting of 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl, wherein any 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, or 5-10 membered heteroaryl, wherein any 3-10 membered carbocyclyl, 3-10 membered heterocycle, 6-10 membered aryl, and 5-10 membered heteroaryl is optionally substituted with halo, hydroxy, cyano, oxo, —OR, —NRR, —C(O)R, —C(O)OR, —C(O)NRR, or C-Calkyl that is optionally substituted with halo, hydroxy, cyano, oxo or C-Calkoxy.'}21. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.22. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient in need thereof a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.23. The method of claim 22 , wherein the disease or condition is asthma.24. The method of claim 22 , wherein the Janus kinase is JAK1. This application is a continuation of U.S. application Ser. No. 16/181,228 filed on Nov. 5, 2018, ...

Smart And Grid-Flexible Power Inverters

A method and apparatus is disclosed that can intelligently invert DC power from single or multiple DC sources to single-phase, split-phase, or three-phase AC power, supply the AC power to the electric power grid when the grid is on, or supply AC power to electric devices or loads when the grid is down. A Smart and Grid-Flexible Power Inverter, or On/Off-Grid Power Inverter, is disclosed that can work in either the on-grid or off-grid mode, and switch back and forth between the two modes manually or automatically depending on the power grid conditions. The system provides a simple and cost-effective solution for areas where the power grid has frequent outages or long downtimes. 1. An on/off-grid power inverter , comprising:a) one or multiple DC input ports;b) an on-grid AC output port connected to the electric grid;c) an off-grid AC output port connected to an off-grid AC circuit; andd) a DC-AC inverter constructed and arranged to receive DC power from the one or multiple DC input ports, invert the DC power to AC power, and supply AC power through said on-grid AC output port to the electric grid in on-grid mode when grid is on, or supply AC power through said off-grid AC output port to power AC loads in the off-grid AC circuit in off-grid mode when grid is down.2. The inverter of claim 1 , in which the DC input ports are arranged to connect to multiple DC sources including photovoltaic solar panels claim 1 , wind generators claim 1 , or batteries claim 1 , or any combination thereof.3. The inverter of claim 1 , in which the on-grid output and off-grid output of the on/off-grid power inverter is single-phase AC.4. The inverter of claim 1 , in which the on-grid output and off-grid output of the on/off-grid power inverter is three-phase AC.5. The inverter of claim 1 , further comprising:a) for each AC output port, an internal AC powerline that conducts the AC power from the DC-AC inverter to the grid or to corresponding AC loads through an external AC powerline;b) for ...

Maximizing Power Production at Low Sunlight by Solar Power Mini-Inverters

A method and apparatus is disclosed for maximizing power production for solar power systems when there is low sunlight during sunrise, sunset, clouding, partial shading, and other low irradiance conditions. A multiple-channel solar power Mini-Inverter can work in the low power mode when there is low sunlight, take power from one solar panel to supply DC power to its internal electronic circuits, and also invert the DC power from the remaining connected solar panels to single-phase or three-phase AC power feeding to the electrical grid or powering AC loads. This invention can significantly reduce the required startup and shutdown irradiance and DC power for the solar power inverter, avoid undesirable shutdowns due to partial shading, and allow the inverter to run in power generation mode for a few more hours each day.

Online Surveillance System to Protect Solar Power Plants

A method and apparatus is disclosed that can monitor the solar power inverters in real-time both day and night, and generate surveillance alarms and actions when a solar power inverter is removed or disconnected from the AC powerline for unknown reasons. It offers a low cost and reliable surveillance means to help guard a residential-scale, commercial-scale, or utility-scale solar power system in real-time at all times. 1. A multiple channel DC-to-AC power inverter , comprising:a) at least two DC power input ports;b) an AC power output port arranged to supply AC power to the electric grid;c) for each DC power input port, a DC-DC boost converter arranged to convert the voltage of a solar panel to a higher DC voltage suitable for inversion;d) a DC power combiner connected to the DC-DC boost converters for combining the DC output from all DC-DC boost converters and allowing the DC-DC boost converters to connect in parallel so that all DC currents are added together;e) a DC-AC inverter connected to said DC power combiner and arranged to invert the DC power to AC power;f) an internal AC powerline that allows the generated AC power to be sent to the grid through an external AC powerline;g) a load interface circuit connected to the DC-AC inverter and to the internal AC powerline, said load interface circuit being arranged to filter high-frequency components out of the DC-AC inverter's AC output;h) a DC power supply connected to the DC power combiner, an AC/DC power supply connected to the external AC powerline, and a power supply selector, arranged to work together and supply DC power to internal electronic circuits of the power inverter either by the DC power supply with input power from one or more solar panels or by the AC/DC power supply with input power from the grid through the external AC powerline;i) a digital microcontroller connected to the DC-DC boost converters, DC-AC inverter, and load interface circuit, said microcontroller arranged to perform one or more of ...

Smart and Scalable Lunar Power Inverters

A method and apparatus is disclosed for solar power generation when irradiance is low and unstable due to sunrise, sunset, clouding, partial shading, warped solar module surfaces, moving solar modules, and other low or varying irradiance conditions. A multi-channel solar power inverter connected to multiple solar modules can work in a “Lunar Power Mode”, inverting DC power induced from the sky, street lights, or surrounding environment to AC power by using a unique rotating power pulling technology. This allows the inverter to dynamically adapt to irradiance variations and generate AC power under complex irradiance conditions. A UPS (uninterruptible power supply) works with a DC power supply to provide DC power to the internal electronic circuits of the inverter allowing it to run in normal power, low power, or lunar power modes. 1. A multiple channel DC-to-AC power inverter , comprising:a) at least two DC power input ports;b) an AC power output port arranged to supply AC power to the electric grid;c) for each DC power input port, a DC-DC boost converter arranged to convert the voltage of a solar module to a higher DC voltage suitable for inversion;d) a DC power combiner connected to the DC-DC boost converters for combining the DC output from all DC-DC boost converters and allowing the DC-DC boost converters to connect in parallel so that all DC currents are added together;e) a DC-AC inverter connected to said DC power combiner and arranged to invert the DC power to AC power;f) an internal AC powerline that allows the generated AC power to be sent to the grid through an external AC powerline;g) a load interface circuit connected to the DC-AC inverter and to the internal AC powerline, said load interface circuit being arranged to filter high-frequency components out of the DC-AC inverter's AC output;h) a UPS (uninterruptible power supply) connected to the DC power combiner and a DC power supply connected to the UPS, arranged to work together and supply DC power to ...

Inhaled powder formulations

Compounds of Formula (00A) and salts thereof, wherein R 1 , R 2 R 3 , R 4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

SMART AND ON/OFF-GRID POWER INVERTERS

A method and apparatus is disclosed that can intelligently invert DC power from single or multiple DC sources to single-phase, split-phase, or three-phase AC power, supply the AC power to the electric power grid when the grid is on, or supply AC power to electric devices or loads when the grid is down. A Smart and Grid-Flexible Power Inverter, or On/Off-Grid Power Inverter, is disclosed that can work in either the on-grid or off-grid mode, and switch back and forth between the two modes manually or automatically depending on the power grid conditions. The system provides a simple and cost-effective solution for areas where the power grid has frequent outages or long downtimes. 1. A scalable DC to AC power inversion system for providing AC power to the electric grid or to an off-grid AC circuit respectively from a plurality of individual DC power sources each having a DC output port , comprising:a) at lease one on-grid power inverter, each having at least one DC input port, an on-grid AC input port, and an on-grid AC output port;b) at least one on/off-grid power inverter, each having at least one DC input port, an on-grid AC output port, and an off-grid AC output port;c) the on-grid AC output port of each inverter being connected in a daisy chain to the on-grid AC input port of the next inverter, except for the on-grid AC output port of the first inverter being connected to the grid;d) said on-grid AC output port of the first inverter being arranged to supply AC power produced by all inverters to the grid when the grid is on;e) the off-grid AC output port of each on/off-grid power inverter being connected to an off-grid AC circuit and arranged to supply AC power to AC loads in the off-grid circuit when grid is down; andf) whereby said system is incrementally scalable by adding or subtracting DC power sources and daisy-chained inverters.2. The system of claim 1 , further comprising:a) a first DC power source connected to one of said DC power input ports of one of said ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 12. A compound of claim 1 , wherein R claim 1 , Rand Rare each hydrogen.13. The compound of claim 1 , wherein Aris phenylene or pyrazolylene.15. The compound of claim 1 , wherein —X—Ris —N(R)—(CRR)—R.16. The compound of claim 15 , wherein:{'sup': 1b', 'x1', 'y1', '1a', '9', 'a', 'b, 'sub': 1', '6', '1', '6', '1', '6', '1', '6, '(1) Ris C-Calkyl optionally substituted by C-Calkoxy, p is 0-3, Rand Rare each independently hydrogen or C-Calkyl, Ris C-Calkyl and Ris NRR; or'}{'sup': 1b', 'x1', 'y1', '1a', '9, 'sub': 1', '6', '1', '6', '1', '6, '(2) Ris C-Calkyl optionally substituted by C-Calkoxy, p is 0-3, Rand Rare each independently hydrogen or C-Calkyl, and Ris 3-11 membered heterocyclyl optionally substituted by R; or'}{'sup': 1a', '1b', '9, '(3) p is 0 and Rand Rare joined to form a 3-11 membered heterocyclyl optionally substituted by R.'}17. The compound of claim 1 , wherein the optional substituents of said optionally substituted C-Calkyl of Ror optionally substituted 3-11 membered heterocyclyl of Rare selected from OH; halogen; CN; NRR; C-Calkyl optionally substituted by halogen; C-Ccycloalkyl; C-Calkoxy; phenyl; 3-11 membered heterocyclyl optionally substituted by C-Calkyl or NRR; C(O)C-Calkyl; and C(O)-3-11 membered heterocyclyl optionally substituted by C-Calkyl.19. The compound of claim 15 , wherein Ris hydrogen or CH.21. A compound selected from Table I claim 15 , Table II claim 15 , or Table III.22. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.23. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of .24. The method of claim 23 , wherein the disease or ...

Method for preparing optical metasurfaces

The present application discloses a method for preparing optical metasurfaces, wherein the method is performed based on nano-imprinting, and the template used in the method is an imprinting template with patterns of meta-atoms. The method for preparing optical metasurfaces provided by the present application can replace the electron beam lithography method used in fabricating meta-atoms, greatly reducing the costs, and greatly reducing the production time. The method provided by the present application significantly improves the production cost and the production time, achieving a low-cost, large-scale fabrication of metasurface-based optical elements within a short time, and having good industrialization prospects.

SMART RENEWABLE ENERGY SYSTEM WITH GRID AND DC SOURCE FLEXIBILITY

A method and apparatus is disclosed relating to smart renewable power generation systems with grid and DC source flexibility that can (1) intelligently and selectively pull power from one or multiple DC sources including solar panels, wind generators, and batteries based on certain criteria; (2) invert DC power to AC power; (3) supply the AC power to the electric grid or to an off-grid electric circuit to power AC loads; (4) supply DC power through one or multiple DC output ports to power DC loads; and (5) charge batteries. Various types of on-grid, off-grid, and on/off-grid DC flexible power inverters are described to demonstrate the innovation for delivering flexible, cost-effective, and user-friendly power generation systems to harvest any form of renewable energy available and convert it to usable electricity. 1. A scalable DC to AC power inversion system for providing AC power to an electric grid from a plurality of individual DC power sources each having a DC output port , comprising:a) at lease one on-grid power inverter, each having an on-grid AC output port and multiple DC input ports constructed and arranged to be connected to multiple DC power sources including at least one photovoltaic solar panel, at least one wind generator, or at least one battery, or any combination thereof;b) each power inverter being constructed and arranged to pull DC power from one or multiple DC input ports based on pre-defined DC source selection criteria;c) the on-grid AC output port of each inverter being combined in parallel to supply AC power to the grid; andd) whereby said system is incrementally scalable by adding or subtracting DC power sources and inverters.2. The scalable DC to AC power inversion system of claim 1 , in which the DC source selection criteria of each on-grid power inverter comprises:(a) maximizing the harvest of solar and wind energy and supplying generated AC power to the electric grid;(b) pulling power or stop pulling power from the battery based on ...

COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy. 145.-. (canceled)47. The Newcastle disease virus of claim 46 , wherein the virus is a modified 73T strain.48. The Newcastle disease virus of claim 46 , wherein the modified FPCS is R116: H-N-R-T-K-R/F-I(SEQ ID NO: 5).49. The Newcastle disease virus of claim 46 , wherein the virus further comprises an increased HN-L intergenic region comprising a non-coding sequence between 50-318 nucleotides in length.50. The Newcastle disease virus of claim 49 , wherein the virus further comprises an increased HN-L intergenic region comprising a non-coding sequence which is 60 claim 49 , 102 claim 49 , 144 claim 49 , 198 claim 49 , or 318 nucleotides in length.51. The Newcastle disease virus of claim 49 , wherein the virus further comprises an increased HN-L intergenic region comprising a non-coding sequence which is 198 nucleotides in length.52. The Newcastle disease virus of claim 49 , wherein the non-coding sequence is derived from a paramyxoviruses type-1 (APMV-1) claim 49 , a respiratory syncytial virus (RSV) claim 49 , or a random sequence.53. The Newcastle disease virus of claim 46 , wherein the virus comprises one or more heterologous polynucleotide sequences inserted at the P-M junction and/or the HN-L junction.54. The Newcastle disease virus of claim 53 , wherein the heterologous polynucleotide sequence is a transgene encoding a polypeptide that enhances the oncolytic properties of the virus.55. The Newcastle disease virus of claim 53 , wherein the ...

POWER INVERTERS WITH MULTIPLE INPUT CHANNELS

A method and apparatus is disclosed for intelligently inverting DC power from DC sources such as photovoltaic (PV) solar modules to single-phase or three-phase AC power to feed the power grid for electricity generation. A power inverter with multiple input channels or input ports that can connect to multiple DC sources is disclosed. 1. A DC-to-AC power inverter , comprising:a) one DC power input port having one DC power source connected thereto;b) one AC power output port arranged to supply AC power to the AC power grid;c) a DC-DC boost converter connected to said DC power source and arranged to convert the power source voltage to a higher DC voltage suitable for inversion;d) a DC-AC inverter connected to said DC-DC boost converter and arranged to invert the DC power to AC power with voltage higher than the incoming AC power voltage;e) an internal AC powerline that combines the generated AC power with the external AC power from the AC power grid;f) a load interface circuit connected to said DC-AC inverter and to said internal AC powerline, said load interface circuit being arranged to filter high-frequency components out of the said DC-AC inverter's AC output;g) an MFA microcontroller connected to said DC-DC boost converter, DC-AC inverter, and load interface circuit, said microcontroller arranged to monitor the DC boost voltage, control the DC-DC boost converter, perform maximum power point tracking (MPPT), perform DC-AC inversion and AC power synchronization, monitor AC current and voltage for generated power amount and status, perform powerline communications, and perform logic controls such as AC powerline switching and isolation;h) a powerline modem connected to said microcontroller and said internal AC powerline through an interface circuitry for transmitting and receiving performance data between said microcontroller and said power grid;i) a line sensing circuit connected to said internal AC powerline and said microcontroller for detecting the phase and zero- ...

COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy. 1. An attenuated Newcastle disease virus (NDV) comprising an F protein cleavage site derived from glycoprotein B (gB) of cytomegalovirus (CMV) (S116).3. The attenuated Newcastle disease virus of or , wherein the attenuated virus strain is a modified 73T strain.4. The attenuated Newcastle disease virus of or , wherein the attenuated NDV virus is r73T-R116 virus.5. The attenuated Newcastle disease virus of or , wherein the virus comprises an increased HN-L intergenic region.6. The attenuated Newcastle disease virus of any of - , wherein the HN-L intergenic region comprises a non-coding sequence between at least about 50-300 amino nucleotides in length.7. The attenuated Newcastle disease virus of claim 6 , wherein the non-coding sequence is derived from a paramyxoviruses type-1 (APMV-1) claim 6 , a respiratory syncytial virus (RSV) or a random sequence.8. The attenuated Newcastle disease virus of claim 6 , wherein the HN and L intergenic non-coding sequence is 60 claim 6 , 102 claim 6 , 144 claim 6 , 198 claim 6 , or 318 nt in length.9. The attenuated Newcastle disease virus of any of - claim 6 , wherein the virus comprises one or more heterologous polynucleotide sequences inserted at the P-M junction and/or the HN-L junction.10. The attenuated Newcastle disease virus of claim 9 , wherein the virus comprises two or more heterologous polynucleotide sequences claim 9 , wherein at least one heterologous polynucleotide sequence is inserted at the P-M junction ...

8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , wherein Ris —C(O)—NH—(C1-C6 alkyl optionally substituted by halogen claim 1 , OH or CN) or —C(O)-(azetidinyl optionally substituted by C1-C6 alkyl or C1-C6 haloalkyl) claim 1 , or a pharmaceutically acceptable salt thereof.4. The compound of claim 1 , wherein Ris —(C0-C6 alkylene)-R claim 1 , or a pharmaceutically acceptable salt thereof.5. The compound of claim 4 , wherein Ris 3-10 membered cycloalkyl claim 4 , 3-10 membered heterocycloalkyl or phenyl claim 4 , where in Ris optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkoxy or C1-C6 thioalkyl claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , C1-C6 thioalkyl optionally substituted by halogen claim 4 , —(C0-C6 alkylene)-NRR claim 4 , —(C0-C6 alkylene)-3-7 membered cycloalkyl claim 4 , —(C0-C6 alkylene)-(3-10 membered heterocycloalkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) claim 4 , —(C0-C6 alkylene)-(phenyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) or —(C0-C6 alkylene)-(5-6 membered heteroaryl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) claim 4 , or a pharmaceutically acceptable salt thereof.6. The compound of claim 4 , wherein Ris 5-6 membered heteroaryl optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkoxy or C1-C6 thioalkyl claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , C1-C6 thioalkyl optionally ...

SELF-ORGANIZING MULTI-STREAM FLOW DELIVERY PROCESS AND ENABLING ACTUATION AND CONTROL

A Self-Organizing Multi-Stream Flow Delivery Process and Enabling Actuation and Control are introduced. The method and apparatus of building a general-purpose self-organizing multi-stream flow delivery process are presented. As a case example, an actuation and control system to control a multi-stream liquid flow delivery process using Self-Organizing Actuation and Control Units (SOACU) is described. 1. A self-organizing multi-stream flow delivery process control system , comprising:a) a multivariable self-organizing actuation and control unit (SOACU); and i) a main liquid flow stream,', 'ii) a flow pump on the main liquid flow stream,', 'iii) a pressure valve on the main liquid flow stream,', 'iv) a pressure transducer that can measure the differential pressure of the pressure valve,', 'v) a plurality of sub liquid flow streams, and', 'vi) a flow valve on each of the sub liquid flow streams., 'b) a multi-stream liquid flow delivery process, including2. The self-organizing multi-stream flow delivery process control system of claim 1 , in which the multivariable self-organizing actuation and control unit (SOACU) comprises:a) a pressure controller;b) a pressure process variable;c) a pressure control output to manipulate the pressure valve;d) a flow controller for each sub liquid flow stream;e) a flow process variable for each sub liquid flow stream;f) a flow control output for each sub liquid flow stream to manipulate its corresponding flow valve; andg) a user selectable setpoint for each sub liquid flow stream.3. The self-organizing multi-stream flow delivery process control system of claim 2 , in which the multivariable self-organizing actuation and control unit (SOACU) receives a differential pressure measurement signal for the main liquid flow stream and a flow measurement signal for each of the sub liquid flow streams.4. The self-organizing multi-stream flow delivery process control system of claim 2 , in which the multivariable self-organizing actuation and ...

METHOD AND APPARATUS OF SELF-ORGANIZING ACTUATION AND CONTROL

A Self-Organizing Process Control Architecture is introduced with a Sensing Layer, Control Layer, Actuation Layer, Process Layer, as well as Self-Organizing Sensors (SOS), Self-Organizing Actuators (SOA), and Self-Organizing Actuation and Control Units (SOACU). The method and apparatus of SOA and SOACU for process control are presented. A control system as a case example for a gas mixing process is described using the unique SOA and SOACU approaches. A 2x1 Robust MFA (Model-Free Adaptive) controller as a key component of the SOACU is also disclosed. 1. A self-organizing process control system , comprising:a) a control layer that includes one or multiple automatic controllers for controlling various process variables;b) a sensing layer that includes one or multiple sensors for measuring various process variables;c) an actuation layer that includes one or multiple actuators that take control command signals from the controllers and manipulate certain process inputs or manipulated variables;d) a process layer that includes physical processes or systems with inputs and outputs that have dynamic relationships;e) one or more of a self-organizing sensor (SOS) and a self-organizing actuator (SOA); andf) one or more self-organizing actuation and control units (SOACUs).2. The control system of claim 1 , in which f) comprises a multivariable self-organizing actuation and control unit (SOACU).3. The control system of claim 1 , comprising a self-organizing sensor (SOS) characterized by one or more of:a) having one or multiple inputs from the process layer;b) having one or multiple inputs from the sensing layer;c) sending its output to the sensing layer; andd) sending its output to the control layer.4. The control system of claim 1 , comprising a self-organizing actuator (SOA) characterized by one or more of:a) taking commands from the control layer;b) having inputs from the sensing layer; andc) manipulating one manipulated variable or manipulating multiple manipulated variables ...

Smart Renewable Power Generation System With Grid and DC Source Flexibility

A method and apparatus is disclosed relating to smart renewable power generation systems with grid and DC source flexibility that can (1) intelligently and selectively pull power from one or multiple DC sources including solar panels, wind generators, and batteries based on certain criteria; (2) invert DC power to AC power; (3) supply the AC power to the electric grid or to an off-grid electric circuit to power AC loads; (4) supply DC power through one or multiple DC output ports to power DC loads; and (5) charge batteries. Various types of on-grid, off-grid, and on/off-grid DC flexible power inverters are described to demonstrate the innovation for delivering flexible, cost-effective, and user-friendly power generation systems to harvest any form of renewable energy available and convert it to usable electricity. 1. An on/off-grid DC source flexible power inverter , comprising:a) multiple DC input ports constructed and arranged to be connected to multiple DC sources including at least one photovoltaic solar panel, at least one wind generator, or at least one battery, or any combination thereof;b) an on-grid AC output port constructed and arranged to be connected to an electric grid;c) an off-grid AC output port constructed and arranged to be connected to an off-grid AC circuit; andd) a DC-AC inverter constructed and arranged to receive DC power from one or multiple DC input ports based on pre-defined DC source selection criteria, invert the DC power to AC power, and supply AC power through said on-grid AC output port to the electric grid in on-grid mode when grid is on, or supply AC power through said off-grid AC output port to power AC loads in the off-grid AC circuit in off-grid mode when grid is down.2. The on/off-grid DC source flexible power inverter of further comprising an on-grid AC input port coupled with the on-grid AC output port.3. The on/off-grid DC source flexible power inverter of claim 1 , in which the on-grid output and off-grid output of the on/ ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 1. A compound selected from the group consisting ofN-methyl-4-[[8-(4-methyl-4-phenyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-cyclohexyl-4-hydroxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-hydroxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochlorideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]bhenzamide4-[[8-(4-methoxy-4-phenyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-hydroxy-4-methyl-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-hydroxy-4-phenyl-azepan-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-methoxy-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-acetamido-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide;hydrochloride4-[[8-(4-acetylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamide4-[[8-(4-cyano-1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]-N-methyl-N-(1-methyl-4-piperidyl)benzamideN-methyl-N-(1-methyl-4-piperidyl)-[4-[[8-(1-piperidyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamide;dihydrochlorideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(4-phenyl-2,3,6,7-tetrahydroazepin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]benzamideN-methyl-N-(1-methyl-4-piperidyl)-4-[[8-(5-phenyl-2,3,4,7-tetrahydroazepin-1 ...

5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein. 12. The compound of claim 1 , wherein Xand Xare independently selected from the group consisting of 3-6-membered cycloalkyl claim 1 , 6-10 membered aryl claim 1 , 5-6 membered heterocycloalkenyl claim 1 , and 5-10 membered heteroaryl claim 1 , wherein each of Xand Xare independently optionally substituted by Y.13. The compound of claim 1 , wherein either Xor Xis a 3-11 membered heterocycloalkyl optionally substituted by Y.14. The compound of claim 1 , wherein Ring Q is (i).15. The compound of claim 1 , wherein tis 0.16. The compound of claim 1 , wherein tis 1.17. The compound of claim 1 , wherein Ring Q is (ii).18. The compound of claim 1 , wherein tis 0.19. The compound of claim 1 , wherein tis 1.20. The compound of claim 1 , wherein R claim 1 , Rand Rare each H.21. The compound of claim 1 , wherein Ris NH.22. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 or 1 claim 1 , and R claim 1 , Rand Rare each H.23. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 1 claim 1 , and Xis NRR claim 1 , wherein Rand Rare each independently H claim 1 , C-Calkyl optionally substituted with 5-6 membered heteroaryl claim 1 , or 3-6 membered cycloalkyl optionally substituted by OH claim 1 , halo claim 1 , CN claim 1 , or C-Calkyl optionally substituted by OH.24. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 claim 1 , and Xis C-Calkyl or 3-6 membered cycloalkyl claim 1 , wherein Xis optionally substituted by —NRR claim 1 , wherein Rand Rare independently H or C-Calkyl.25. The compound of claim 1 , selected from Table 1.26. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.27. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering ...

Smart Microgrids and Dual-Output Off-Grid Power Inverters with DC Source Flexibility

A method and apparatus is disclosed relating to smart microgrids supported by dual-output off-grid power inverters with DC source flexibility that can (1) intelligently and selectively pull power from one or multiple DC sources including solar panels, wind generators, and batteries based on certain criteria; (2) invert DC power to AC power; (3) supply the AC power to two off-grid circuits individually to power various types of AC loads that require different AC voltages, power quality, and power levels; (4) supply DC power through one or multiple DC output ports to power DC loads; and (5) charge batteries. Two or multiple dual-output off-grid power inverters can daisy-chain to form a group to support a larger microgrid which is ideal for off-grid AC Level 1 and Level 2 EV charging. 1. A dual-output off-grid power inverter , comprising:a) one or multiple DC input ports;b) an AC output port 1 connected to an off-grid AC circuit 1 and arranged to supply AC power to type 1 AC loads when working in off-grid mode 1;c) an AC output port 2 connected to an off-grid AC circuit 2 and arranged to supply AC power to type 2 AC loads when working in off-grid mode 2; andd) a DC-AC inverter constructed and arranged to receive DC power from the one or multiple DC input ports, invert the DC power to AC power, and supply AC power through said AC output port 1 for type 1 AC loads or AC output port 2 for type 2 AC loads.2. The inverter of claim 1 , in which the DC input ports are arranged to connect to multiple DC sources including at least one photovoltaic solar panel claim 1 , at least one wind generator claim 1 , or at least one battery claim 1 , or any combination thereof claim 1 , whereby the said inverter can pull power from the connected DC sources based on pre-defined DC source selection criteria.3. The inverter of claim 1 , further comprising:a) a DC power supply coupled to the one or multiple DC input ports; andb) one or multiple DC output ports coupled to the DC power supply ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 1 claim 1 , or mis 2 and mis 1.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': 6', '7, 'Rand Rare attached to the ring at the same carbon atom; or'}{'sup': 6', '7, 'sub': 1', '6', '1', '6, 'Ris C-Calkyl or C-C-alkoxy, and Ris optionally substituted phenyl; or'}{'sup': 6', '7', 'a', 'b, 'sub': 1', '6', '3', '6', '0', '6', '0', '6', '0', '6, 'Ris C-Calkyl, C-Ccycloalkyl or optionally substituted phenyl and Ris OH, (C-Calkylene) C(O)NRR, (C-Calkylene) CN or —O— (C-Calkyl)CN; or'}{'sup': 6', '7', 'a', 'b', 'a', 'b, 'sub': 0', '6', '0', '6', '1', '6', '3', '6', '0', '6', '1', '6, 'Ris hydrogen and Ris selected from (C-Calkylene) C(O)NRR, (C-Calkylene) CN, C-C-alkoxy, —O—(C-Ccycloalkyl), —O—(C-Calkylene)C(O)NRR, and —O—(C-Calkylene)CN; or'}{'sup': 6', '7, 'Rand Rtogether form a 3-11 membered heterocycloalkyl optionally substituted by oxo.'}6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein one or both of Rand Ris located at the para position of the ring.8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 2 claim 1 , or mis 2 and mis 1 claim 1 , or mis 1 and mis 1.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris H and Rand is substituted phenyl.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein mis 1 and mis 1 claim 11 , or mis 1 and mis 2 claim 11 , or mis 1 and mis 0.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein mis 1 and mis 1 claim 14 , mis 1 and mis 1 claim 14 , or mis 1 and mis 2.16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.3. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris CH.4. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.5. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.6. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein R claim 1 , R claim 1 , Rand Rare each hydrogen.7. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein R2 is C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , C-Ccycloalkyl claim 1 , or —OR claim 1 , wherein Ris optionally substituted by one or more groups independently selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , cyano claim 1 , hydroxy and oxo.8. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris selected from the group consisting of halogen claim 1 , C-Chaloalkyl and C-Chaloalkoxy.10. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a stereoisomer or pharmaceutically acceptable salt thereof.11. The method of claim 10 , wherein the disease or condition is cancer claim 10 , stroke claim 10 , diabetes ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds of Formula (00A) and salts thereof, wherein R, RR, Rand n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of wherein Ris H claim 1 , —(C-Calkyl)R claim 1 , (C-Calkyl)NRR claim 1 , —(C-Calkyl)C(O)R claim 1 , or —(C-Calkyl)C(O)OR claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.3. The compound of wherein Ris H claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.4. The compound of wherein Ris C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , —(C-Calkyl)CN claim 1 , —(C-Calkyl)OR claim 1 , —(C-Calkyl)R claim 1 , —(C-Calkyl)SR claim 1 , —(C-Calkyl)NRR claim 1 , —(C-Calkyl)OCF claim 1 , —(C-Calkyl)CF claim 1 , —(C-Calkyl)NO claim 1 , —(C-Calkyl)C(O)R claim 1 , —(C-Calkyl)C(O)OR claim 1 , —(C-Calkyl)C(O)NRR claim 1 , —(C-Calkyl)NRC(O)R claim 1 , —(C-Calkyl)S(O)R claim 1 , —(C-Calkyl)NRS(O)R claim 1 , —(C-Calkyl)S(O)NRR claim 1 , —(C-Calkyl)(5-6-membered heteroaryl) or —(C-Calkyl)phenyl claim 1 , wherein Ris optionally substituted by one or more groups independently selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , oxo claim 1 , —CF claim 1 , —(C-Calkyl)ORand —(C-Calkyl)NRR claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.5. The compound of wherein Ris C-Calkyl claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.6. The compound of wherein Ris —(C-Calkyl)R claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.7. The compound of wherein Ris —(C-Calkyl)NRR claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.8. The compound of wherein Ris —(C-Calkyl)C(O)R claim 1 , or a ...

8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , wherein Ris —C(O)—NH—(C1-C6 alkyl optionally substituted by halogen claim 1 , OH or CN) or —C(O)-(azetidinyl optionally substituted by C1-C6 alkyl or C1-C6 haloalkyl) claim 1 , or a pharmaceutically acceptable salt thereof.4. The compound of claim 1 , wherein Ris —(C0-C6 alkylene)-R claim 1 , or a pharmaceutically acceptable salt thereof.5. The compound of claim 4 , wherein Ris 3-10 membered cycloalkyl claim 4 , 3-10 membered heterocycloalkyl or phenyl claim 4 , where in Ris optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkoxy or C1-C6 thioalkyl claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , C1-C6 thioalkyl optionally substituted by halogen claim 4 , —(C0-C6 alkylene)-NRR claim 4 , —(C0-C6 alkylene)-3-7 membered cycloalkyl claim 4 , —(C0-C6 alkylene)-(3-10 membered heterocycloalkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) claim 4 , —(C0-C6 alkylene)-(phenyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) or —(C0-C6 alkylene)-(5-6 membered heteroaryl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkyl or C1-C6 haloalkyl) claim 4 , or a pharmaceutically acceptable salt thereof.6. The compound of claim 4 , wherein Ris 5-6 membered heteroaryl optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , CN claim 4 , OH claim 4 , C1-C6 alkyl optionally substituted by halogen claim 4 , OH claim 4 , CN claim 4 , C1-C6 alkoxy or C1-C6 thioalkyl claim 4 , C1-C6 alkoxy optionally substituted by halogen claim 4 , C1-C6 thioalkyl optionally ...

THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein. 4. The compound of claim 1 , or a salt or stereoisomer thereof claim 1 , wherein ring A is not optionally substituted.5. The compound of claim 1 , or a salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.6. The compound of claim 1 , or a salt or stereoisomer thereof claim 1 , wherein Ris hydrogen and Ris C-Calkyl.9. The compound claim 1 , salt or stereoisomer of claim 1 , wherein Ris —C(O)NRRor —C(O)R.12. A pharmaceutical composition comprising a compound of claim 1 , or a salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.13. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a stereoisomer thereof claim 1 , or a pharmaceutically acceptable salt thereof.14. The method of claim 13 , wherein the disease or condition is asthma.15. The method of claim 13 , wherein the Janus kinase is JAK1. This application is a continuation of International Application No. PCT/EP2016/081553, filed Dec. 16, 2016, which claims the benefit of priority to International Application No. PCT/CN2015/097932, filed Dec. 18, 2015, each of which is incorporated by reference herein in its entirety.The field of the invention pertains to compounds that are inhibitors of a Janus kinase, such as JAK1, as well as compositions containing these compounds, and methods of use including, but not limited to, diagnosis or treatment of patients suffering from a condition responsive to the inhibition of a JAK kinase.Cytokine pathways mediate a broad range of biological functions, including many aspects of inflammation and immunity. Janus kinases (JAK), including JAK1, JAK2, JAK3 and TYK2, are cytoplasmic protein kinases that ...

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. 3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 1 claim 1 , or is 2 and mis 1.4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': 6', '7, 'Rand Rare attached to the ring at the same carbon atom; or'}{'sup': 6', '7, 'sub': 1', '6', '1', '6, 'Ris C-Calkyl or C-C-alkoxy, and Ris optionally substituted phenyl; or'}{'sup': 6', '7', 'a', 'b, 'sub': 1', '6', '3', '6', '0', '6', '0', '6', '0', '6, 'Ris C-Calkyl, C-Ccycloalkyl or optionally substituted phenyl and Ris OH, (C-Calkylene)C(O)NRR, (C-Calkylene)CN or —O—(C-Calkyl)CN; or'}{'sup': 6', '7', 'a', 'b', 'a', 'b, 'sub': 0', '6', '0', '6', '1', '6', '3', '6', '0', '6', '1', '6, 'Ris hydrogen and Ris selected from (C-Calkylene)C(O)NRR, (C-Calkylene)CN, C-C-alkoxy, —O—(C-Ccycloalkyl), —O—(C-Calkylene)C(O)NRR, and —O—(C-Calkylene)CN; or'}{'sup': 6', '7, 'Rand Rtogether form a 3-11 membered heterocycloalkyl optionally substituted by oxo.'}6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein one or both of Rand Ris located at the para position of the ring.8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein mis 1 and mis 2 claim 1 , or mis 2 and mis 1 claim 1 , or mis 1 and mis 1.9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris H and Rand is substituted phenyl.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein mis 1 and mis 1 claim 11 , or mis 1 and mis 2 claim 11 , or mis 1 and mis 0.15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , wherein mls 1 and mis 1 claim 14 , mis 1 and mis 1 claim 14 , or mis 1 and mis 2.16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , ...

5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein. 12. The compound of claim 1 , wherein Xand Xare independently selected from the group consisting of 3-6-membered cycloalkyl claim 1 , 6-10 membered aryl claim 1 , 5-6 membered heterocycloalkenyl claim 1 , and 5-10 membered heteroaryl claim 1 , wherein each of Xand Xare independently optionally substituted by Y.13. The compound of claim 1 , wherein either Xor Xis a 3-11 membered heterocycloalkyl optionally substituted by Y.14. The compound of claim 1 , wherein Ring Q is (i).15. The compound of claim 1 , wherein tis 0.16. The compound of claim 1 , wherein tis 1.17. The compound of claim 1 , wherein Ring Q is (ii).18. The compound of claim 1 , wherein tis 0.19. The compound of claim 1 , wherein tis 1.20. The compound of claim 1 , wherein R claim 1 , Rand Rare each H.21. The compound of claim 1 , wherein Ris NH.22. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 or 1 claim 1 , and R claim 1 , Rand Rare each H.23. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 1 claim 1 , and Xis NRR claim 1 , wherein Rand Rare each independently H claim 1 , C-Calkyl optionally substituted with 5-6 membered heteroaryl claim 1 , or 3-6 membered cycloalkyl optionally substituted by OH claim 1 , halo claim 1 , CN claim 1 , or C-Calkyl optionally substituted by OH.24. The compound of claim 1 , wherein Ring Q is (i) claim 1 , tis 0 claim 1 , and Xis C-Calkyl or 3-6 membered cycloalkyl claim 1 , wherein Xis optionally substituted by —NRR claim 1 , wherein Rand Rare independently H or C-Calkyl.25. The compound of claim 1 , selected from Table 1.26. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.27. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering ...

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R, R, R, R, R, Rand Rare defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient. 3. A pharmaceutical composition comprising a compound of or , or a pharmaceutically acceptable salt or stereoisomer thereof , and a pharmaceutically acceptable carrier , diluent or excipient.4. A method of preventing , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient , comprising administering to the patient a therapeutically effective amount of a compound of or , or a pharmaceutically acceptable salt or stereoisomer thereof.5. The method of claim 4 , wherein the disease or condition is asthma.6. The method of claim 4 , wherein the Janus kinase is JAK1.7. The invention as in hereinbefore described. This patent application is a continuation of U.S. application Ser. No. 15/692,907, filed Aug. 31, 2017, which claims priority to continuation International Application No. PCT/EP2016/054343, filed Mar. 2, 2016, which claims the benefit of International Application No. PCT/CN2016/072287, filed Jan. 27, 2016, U.S. Provisional Appl. No. 62/134,838, filed Mar. 18, 2015, and U.S. Provisional Appl. No. 62/128,234, filed Mar. 4, 2015, each of which is incorporated herein by reference in its entirety.The present invention relates to organic compounds useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of JAK kinases useful for diagnosis ...

5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein. 12. The compound of claim 1 , wherein Xand Xare independently selected from the group consisting of 3-6-membered cycloalkyl claim 1 , 6-10 membered aryl claim 1 , 5-6 membered heterocycloalkenyl claim 1 , and 5-10 membered heteroaryl claim 1 , wherein each of Xand Xare independently optionally substituted by Y.13. The compound of claim 1 , wherein either Xor Xis a 3-11 membered heterocycloalkyl optionally substituted by Y.14. The compound of claim 1 , wherein Ring Q is (i).15. The compound of claim 1 , wherein Ring Q is (ii).16. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.17. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of .18. The method of claim 17 , wherein the disease or condition is asthma.19. The method of claim 17 , wherein the Janus kinase is JAK1.20. A kit claim 1 , comprising the pharmaceutical composition of claim 1 , and printed instructions for administration of the pharmaceutical composition. This application is a continuation of U.S. application Ser. No. 15/820,515 filed on Nov. 22, 2017, which is a continuation of U.S. application Ser. No. 15/424,536, filed Feb. 3, 2017, which is a continuation of U.S. application Ser. No. 15/139,164, filed Apr. 26, 2016, now issued as U.S. Pat. No. 9,604,984, which is a continuation of U.S. application Ser. No. 14/720,323, filed May 22, 2015, now issued as U.S. Pat. No. 9,346,815, which claims the benefit of: U.S. Provisional Application No. 62/130,098, filed Mar. 9, 2015, now expired; U.S. Provisional Application No. 62/101,234, filed Jan. 8, 2015, now expired; U.S. Provisional Application No. 62/002,547, filed May 23, 2014, ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.3. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris CH.4. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.5. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.6. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein R claim 1 , R claim 1 , Rand Rare each hydrogen.7. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein R2 is C-Calkyl claim 1 , C-Calkenyl claim 1 , C-Calkynyl claim 1 , C-Ccycloalkyl claim 1 , or —OR claim 1 , wherein Ris optionally substituted by one or more groups independently selected from the group consisting of halogen claim 1 , C-Calkyl claim 1 , cyano claim 1 , hydroxy and oxo.8. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris selected from the group consisting of halogen claim 1 , C-Chaloalkyl and C-Chaloalkoxy.27. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.28. A compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , for use in the treatment of an inflammatory disease.29. A method of preventing claim 1 , treating or lessening the severity of a disease or condition ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen or —(C-Calkyl)C(O)NRR.3. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Ris hydrogen.4. The compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , wherein Rand Rare each hydrogen.20. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.21. A compound of or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , for use in the treatment of an inflammatory disease.22. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt or stereoisomer thereof.23. The method of claim 22 , wherein the disease or condition is asthma.24. The method of claim 22 , wherein the Janus kinase is JAK1. This application claims the benefit of priority to U.S. Application Ser. No. 62/644,784, filed Mar. 19, 2018, and International Patent Application No. PCT/CN2017/085277, filed May 22, 2017, each of which is incorporated by reference herein in its entirety.The invention relates to compounds that are inhibitors of a Janus kinase, such as JAK1, as well as compositions containing these compounds, and methods of use including, but not ...

TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R, R, R, R, R, Rand Rare defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient. 4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 1 , and a pharmaceutically acceptable carrier claim 1 , diluent or excipient.5. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.6. The method of claim 5 , wherein the disease or condition is asthma claim 5 , rhinitis claim 5 , allergic airway syndrome claim 5 , atopic dermatitis claim 5 , bronchitis claim 5 , rheumatoid arthritis claim 5 , psoriasis claim 5 , contact dermatitis claim 5 , chronic obstructive pulmonary disease or delayed hypersensitivity reaction.7. The method of claim 5 , wherein the Janus kinase is JAK1 claim 5 , JAK2 or JAK3.8. A lot for treating a disease or disorder responsive to the inhibition of a Janus kinase claim 5 , comprising: (a) a first pharmaceutical composition comprising a compound of formula (I); and (b) instructions for use.9. The kit of claim 8 , further comprising; (c) a second pharmaceutical composition claim 8 , the second pharmaceutical composition comprising an agent for treatment of asthma ...

PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring A is an oxo substituted 5-membered carbocycle that is optionally substituted with one or more groups selected from the group consisting of halo claim 1 , cyano claim 1 , nitro claim 1 , C-Calkoxy claim 1 , C-Calkoxycarbonyl claim 1 , C-Calkanoyloxy claim 1 , carboxy claim 1 , and C-Calkyl claim 1 , wherein any C-Calkoxy claim 1 , C-Calkoxycarbonyl claim 1 , C-Calkanoyloxy claim 1 , and C-Calkyl is optionally substituted with one or more groups selected from the group consisting of halo claim 1 , cyano claim 1 , nitro claim 1 , oxo claim 1 , and C-Calkoxy.3. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring A is an oxo substituted 6-membered carbocycle that is optionally substituted with one or more groups selected from the group consisting of halo claim 1 , cyano claim 1 , nitro claim 1 , C-Calkoxy claim 1 , C-Calkoxycarbonyl claim 1 , C-Calkanoyloxy claim 1 , carboxy claim 1 , and C-Calkyl claim 1 , wherein any C-Calkoxy claim 1 , C-Calkoxycarbonyl claim 1 , C-Calkanoyloxy claim 1 , and C-Calkyl is optionally substituted with one or more groups selected from the group consisting of halo claim 1 , cyano claim 1 , nitro claim 1 , oxo claim 1 , and C-Calkoxy.4. The compound or pharmaceutically acceptable salt of claim 1 , wherein ring A is an oxo substituted 5-membered heterocycle that is optionally substituted with one or more groups selected from the group consisting of halo claim 1 , cyano claim 1 , nitro claim 1 , C-Calkoxy claim 1 , C-Calkoxycarbonyl claim 1 , C-Calkanoyloxy claim 1 , ...

PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein. 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein A is substituted with 1-5 R claim 1 , wherein each Ris independently selected from the group consisting of: oxo; cyano; C-Calkyl; —(C-Calkyl)C(O)R claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , C-Calkyl claim 1 , or a 6-membered heterocyclic group claim 1 , optionally substituted with —(C-Calkyl)C(O)OR claim 1 , wherein Ris C-Calkyl; —(C-Calkyl)OR claim 1 , wherein Ris hydrogen or C-Calkyl; —(C-Calkyl)C(O)OR claim 1 , wherein Ris hydrogen or C-Calkyl; —(C-Calkyl)NRR claim 1 , wherein each Rand Ris independently hydrogen or C-Calkyl; and —(C-Calkyl)C(O)NRR claim 1 , wherein each Rand Ris independently hydrogen or C-Calkyl.2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein A is the 6-membered aromatic group.3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein A is the 5-membered heterocyclic group.4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein the 5-membered heterocyclic group is a 5-membered heteroaryl group.5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof claim 4 , wherein the 5-membered heteroaryl group is substituted with 1-5 R claim 4 , wherein R″ is selected from the group consisting of cyano; unsubstituted C-Calkyl; —(C-Calkyl)C(O)OR claim 4 , wherein Ris hydrogen or C-Calkyl; —(C-Calkyl)C(O)R claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , C-Calkyl claim 4 , or a 6-membered heterocyclic group claim 4 , optionally substituted with —(C-Calkyl)C(O)OR claim 4 , wherein Ris C-Calkyl; and —(C-Calkyl)C(O)NRR claim 4 , wherein each Rand Ris independently hydrogen or C-Calkyl.6. The compound of claim 1 , or a pharmaceutically ...

THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF

Methods of using compounds and salts thereof as JAK kinase inhibitors are described herein, including methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. 2. The method of claim 1 , wherein the cancer is squamous cell cancer claim 1 , lung cancer claim 1 , adenocarcinoma of the lung claim 1 , squamous carcinoma of the lung claim 1 , skin keratoacanthoma claim 1 , follicular carcinoma claim 1 , hairy cell leukemia claim 1 , or cancer of the buccal cavity claim 1 , pharynx (oral) claim 1 , lip claim 1 , tongue claim 1 , mouth claim 1 , salivary gland claim 1 , esophageal claim 1 , larynx claim 1 , hepatocellular claim 1 , gastric claim 1 , stomach claim 1 , gastrointestinal claim 1 , small intestine claim 1 , large intestine claim 1 , pancreatic claim 1 , cervical claim 1 , ovarian claim 1 , liver claim 1 , bladder claim 1 , hepatoma claim 1 , breast claim 1 , colon claim 1 , rectal claim 1 , colorectal claim 1 , genitourinary claim 1 , biliary passage claim 1 , thyroid claim 1 , papillary claim 1 , hepatic claim 1 , endometrial claim 1 , uterine claim 1 , salivary gland claim 1 , kidney or renal claim 1 , prostate claim 1 , testis claim 1 , vulval claim 1 , peritoneum claim 1 , anal claim 1 , penile claim 1 , bone claim 1 , multiple myeloma claim 1 , B-cell lymphoma claim 1 , central nervous system claim 1 , brain claim 1 , head and neck claim 1 , Hodgkin's disease claim 1 , polycythemia vera claim 1 , essential thrombocytosis claim 1 , myelofibrosis claim 1 , multiple myeloma claim 1 , B-cell lymphoma claim 1 , and chronic myelogenous leukemia (CML) claim 1 , or cancer of the buccal cavity claim 1 , pharynx (oral) claim 1 , lip claim 1 , tongue claim 1 , mouth claim 1 , salivary gland claim 1 , esophageal claim 1 , larynx claim 1 , hepatocellular claim 1 , gastric claim 1 , stomach claim 1 , gastrointestinal claim 1 , small intestine claim 1 , large intestine claim 1 , ...

COMPOSITION FOR SUBMUCOSAL INJECTION, REAGENT COMBINATION, AND APPLICATIONS THEREOF

Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 μm. The viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection. 1. A composition for submucosal injection , comprising:a biocompatible modified starch in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition, which has a molecular weight from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 μm, wherein the biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches, and composite modified starches; anda pharmaceutically acceptable carrier for injection;wherein, the viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C.2. The composition of claim 1 , wherein the pharmaceutically acceptable carrier for injection is selected from one or more of the group consisting of: physiological saline claim 1 , balanced salt solution claim 1 , glucose solution claim 1 , sterile pyrogen-free water claim 1 , and glycerin.3. The ...

TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF

Compounds of formula (I) 2. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris —(CHR)-het; or —(CHR)—NRR claim 1 , wherein the hetmay be unsubstituted or substituted once with R.3. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris: chloro; difluoromethoxy; methylethio; or cyclopropyl.4. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare hydrogen.5. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rtogether with the atoms to which they are attached form a six-membered ring containing two heteroatoms each independently selected from O claim 1 , N and S.6. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein hetis azetidinyl claim 1 , which may be unsubstituted or substituted once with R.10. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective amount of a compound of or a stereoisomer or pharmaceutically acceptable salt thereof.11. The method of claim 10 , wherein the disease or condition is cancer claim 10 , stroke claim 10 , diabetes claim 10 , hepatomegaly claim 10 , cardiovascular disease claim 10 , multiple sclerosis claim 10 , Alzheimer's disease claim 10 , cystic fibrosis claim 10 , viral disease claim 10 , autoimmune diseases claim 10 , atherosclerosis claim 10 , restenosis claim 10 , psoriasis claim 10 , rheumatoid arthritis claim 10 , inflammatory bowel disease claim 10 , asthma claim 10 , allergic disorders claim 10 , inflammation claim 10 , neurological disorders claim 10 , a hormone-related disease claim 10 , conditions associated with organ transplantation (e.g. claim 10 , transplant ...

PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF

Compounds of formula (I) 2. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein R claim 1 , R claim 1 , Rand Rare hydrogen.3. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris cyanomethyl or methyl.4. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris cyanomethyl.5. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris methyl.6. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris: Calkyl; hydroxy-Calkyl; halo-Calkyl; Calkoxy-Calkyl; Ccycloalkyl; —(CHR)—NRR; het; —(CHR)-het; or phenyl which may be unsubstituted or substituted once with R.7. The compound of claim 1 , wherein Ris Calkyl claim 1 , hydroxy-Calkyl; Calkoxy-Calkyl or halo-Calkyl.8. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris hydroxy-Calkyl or Calkoxy-Calkyl.9. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris 2-hydroxy ethyl claim 1 , difluoromethoxy claim 1 , 3-hydroxyhenyl claim 1 , -methoxyphenyl claim 1 , 2-hydroxypropyl claim 1 , pyridine-4-yl claim 1 , methyl claim 1 , azetidin-yl claim 1 , 2-hydroxy-1-methyl-ethyl claim 1 , methylamino claim 1 , dimethylamino claim 1 , l-methyl-pyrazol-4-yl claim 1 , phenyl claim 1 , pyrazol-4-yl claim 1 , 1-methyl-2-oxo-4-pyridyl claim 1 , or 2-hydroxy-1-methyl-propyl.10. The compound of or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , wherein Ris 2-hydroxy ethyl claim 1 , 2-hydroxypropyl claim 1 , 2-hydroxy-1-methyl-ethyl claim 1 , or 2-hydroxy-1-methyl-propyl.14. A method of preventing claim 1 , treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient claim 1 , comprising administering to the patient a therapeutically effective ...

Isoindole derivatives useful for treating pain, gastrointestinal diseases and cancer

Compounds of formula I or pharmaceutically acceptable salts thereof: [Chemical formula should be inserted here. Please see paper copy] I wherein X, R1, R2, R3, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Influenza hemagglutinin and neuraminidase variants

Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.

Influenza hemagglutinin and neuraminidase variants

Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.

Compounds

Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein A 1 , A 2 , G 1 , G 2 G 3 , R 1 , R 2 , X, Y, Z, m, n and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Piperidine derivatives and their use as muscarinic receptor modulators

Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R 2 , R 3 , X, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Dispersion, alignment and deposition of nanotubes

A dispersible nanocomposite comprising nanotubes associated with nanoplatelets. A method for creating an exfoliated nanotubes solution, aligning nanotubes and depositing them on a substrate or in matrix. In one embodiment, the method includes a nanocomposite of at least one nanotube electrostatically associated with at least one nanoplatelet. The nanoplatelets may be removed from the suspension by altering the ionic strength to create an exfoliated nanotube solution. The exfoliated nanotube solution for injection into microchannel templates and aligned deposition.

Dispersion, alignment and deposition of nanotubes

A dispersible nanocomposite comprising nanotubes associated with nanoplatelets. A method for creating an exfoliated nanotubes solution, aligning nanotubes and depositing them on a substrate or in matrix. In one embodiment, the method includes a nanocomposite of at least one nanotube electrostatically associated with at least one nanoplatelet. The nanoplatelets may be removed from the suspension by altering the ionic strength to create an exfoliated nanotube solution. The exfoliated nanotube solution for injection into microchannel templates and aligned deposition.

Method for dispersion, alignment and deposition of nanotubes

Compositions and methods involving respiratory syncytial virus subgroup b strain 9320

The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g. attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides, Related methods are also described.

Apparatus and method of controlling multi-input-single-output systems

An apparatus and method is disclosed for automatically controlling multi-input-single-output (MISO) systems or processes. The control output signal of a single-input-single-output (SISO) automatic controller is converted by a reverse, sequential or combined split-range setter into a plurality of ranges of signals so that the SISO controller is converted to a single-input-multi-output (SIMO) automatic controller based on certain criteria; and the resulting controller output signals are able to manipulate a plurality of actuators to control one continuous process variable in different operating conditions. Without the need of building process mathematical models, this inventive apparatus and method is useful for automatically controlling unevenly paired multivariable systems or processes where there are more system inputs than outputs including but not limited to pH processes, chemical reactors, and air handling units.

Therapeutic compounds and compositions, and methods of use thereof

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, Alzheimer's disease and/or Schizophrenia

Therapeutic heterocycles

Compounds of formula (I) or (II) wherein R 1 , R 2 , R 3 , R 4 , W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Novel compounds

Compounds of general formula (I), are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

COMPOSITIONS WITH AN ANIMATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR THE TREATMENT OF NEOPLASI

Wood adhesives containing reinforced additives for structural engineering products

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engi-neered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Therapeutic heterocycles

Compounds of formula (I) or (II) wherein R1 , R2 , R3 , R4 , W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Method for the treatment or prevention of Flavivirus infections using nucleoside analogues

The present invention relates to a method for the treatment or prevention of Flavivirus infections using nucleoside analogues in a host comprising administering a therapeutically effective amount of a compound having the formula I or a pharmaceutically acceptable salt thereof.

Wood adhesives containing reinforced additives for structural engineering products

The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Electrical connector assembly

An electrical connector assembly ( 1000 ) includes a first connector ( 100 ) having a first housing ( 1 ) and a plurality of first terminals ( 2 ) fitted in the first housing ( 1 ) and a second connector ( 200 ) having a second housing ( 4 ) and a plurality of second terminals ( 5 ) fitted in the second housing ( 4 ). The first housing ( 2 ) comprises a longitudinal main body ( 11 ) defining a receiving space ( 110 ) and a plurality of first receiving slots ( 115 ) arranged along the longitudinal direction. The first terminals ( 2 ) are received in the first receiving slots ( 115 ). The second housing ( 4 ) comprises a longitudinal base ( 40 ) received in the receiving space ( 110 ) of the first connector ( 1 ) and a plurality of second receiving slots ( 41 ) arranged along the longitudinal direction to receive the second terminals ( 5 ). The receiving space ( 110 ) of the first housing ( 1 ) comprises a plurality of receiving sections ( 116 ) arranged along longitudinal direction, the second housing ( 4 ) of the second connector ( 200 ) comprises a plurality of engaging portions ( 45 ) arranged corresponding to the receiving sections ( 116 ), the engaging sections ( 45 ) are received and retained in the receiving sections ( 116 ).

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.

Composition, kit and method for detecting and typing viruses causing respiratory tract infection and application of composition, kit and method

Reversal imprint technique

Reversal imprint technique

The present invention relates to a method for imprinting a micro-/nano-structure on a substrate, the method comprising (a) providing a mold containing a desired pattern or relief for a microstructure; (b) applying a polymer coating to the mold; and (c) transferring the polymer coating from the mold to a substrate under suitable temperature and pressure conditions to form an imprinted substrate having a desired micro-/nano-structure thereon.

PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR METHODS OF USE

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

bellows and bellows valve sealing assembly comprising the same

MONTAGEM DA VÁLVULA DA TUBULAÇÃO CORRUGADA E VÁLVULA DE TUBULAÇÃO CORRUGADA. Uma montagem de uma tubulação corrugada tendo a montagem de vedação de tubulação corrugada divulgada. A montagem da vedação de tubulação corrugada compreende uma tubulação corrugada interna (3), uma tubulação corrugada externa (4), uma conexão tubular superior (5), uma primeira conexão tubular inferior (2) e uma segunda conexão tubular inferior (1). Uma extremidade da tubulação corrugada interna (3) é fixada com a conexão tubular corrugada superior (5), enquanto a outra extremidade é fixadacom a segunda conexão tubular inferior (1). Uma extremidade do tubo exterior corrugado (3) é fixada com a conexão tubular corrugada superior (5), enquanto a outra extremidade é fixada com a primeira conexão tubular inferior. O tubo exterior corrugada (4) é encoberto pela tubulação corrugada interna (3). A montagem da tubulação corrugada vedada e a válvula de tubulação corrugada têm as vantagens de desenho estrutural racional, poupando custos materiais, encurtando o comprimento da válvula, e encurtando o curso do interruptor de válvula, e são comparativamente favoráveis para locais com limites de altura. ASSEMBLY OF THE CORRUGATED PIPING VALVE AND CORRUGATED PIPING VALVE. An assembly of a corrugated pipe having the disclosed corrugated pipe seal assembly. The assembly of the corrugated pipe seal comprises an internal corrugated pipe (3), an external corrugated pipe (4), an upper pipe connection (5), a first lower pipe connection (2) and a second lower pipe connection (1). One end of the internal corrugated tubing (3) is fixed with the upper corrugated tubing connection (5), while the other end is fixed with the second lower tubular connection (1). One end of the corrugated outer tube (3) is fixed with the upper corrugated tubular connection (5), while the other end is fixed with the first lower tubular connection. The corrugated outer tube (4) is covered by the inner corrugated tubing (3). The assembly of ...

COMPOUNDS 8- (AZETIDIN-1-IL) - [1,2,4] TRIAZOLO [1,5-A] PIRIDINYL, COMPOSITIONS AND METHODS OF USING THEMSELVES

SE REFIERE A COMPUESTOS 8-(AZETIDIN-1-IL)-[1,2,4]TRIAZOLO[1,5-A]PIRIDINILO DE FORMULA (I) O (II) DONDE EL ANILLO A ES FENILO, PIRIDINILO, PIRAZOLILO O ISOQUINOLINILO; EL ANILLO B ES FENILO O HETEROARILO DE 5-6 ELEMENTOS; n ES 0, 1 O 2; R2 ES -C(O)-NH-(ALQUILO C1-C6 SUSTITUIDO OPCIONALMENTE CON HALOGENO, OH O CN), ENTRE OTROS; R3, R4 Y R5 SON CADA UNO H, CH3, CH2CH3, ENTRE OTROS; R6 ES H O ALQUILO C1-C3; R1a ES HALOGENO, ALQUILO C1-C6 SUSTITUIDO OPCIONALMENTE CON HALOGENO, CN O OH, ALCOXI C1-C6, ENTRE OTROS; R1b Y R1c JUNTOS FORMAN UN HETEROCICLOALQUILO DE 3 A 10 ELEMENTOS SUSTITUIDO OPCIONALMENTE CON ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[3-(4-ETIL-1H-PIRAZOL-1-IL)-1-[2-([1-[2-(4-METILPIPERAZIN-1-IL)-2-OXOETIL]-1H-PIRAZOL-4-IL]AMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-IL]AZETIDIN-3-IL]ACETONITRILO; 2-[3-(4,4-DIFLUORO-1-PIPERIDIL)-1-[2-[[1-[2-(4-METILPIPERAZIN-1-IL)-2-OXO-ETIL]PIRAZOL-4-IL]AMINO]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-IL]AZETIDIN-3-IL]ACETONITRILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS QUINASAS DE JANUS (JAK) SIENDO UTILES EN EL TRATAMIENTO DE ASMA REFERS TO COMPOUNDS 8- (AZETIDIN-1-IL) - [1,2,4] TRIAZOLO [1,5-A] FORMULA PIRIDINYL (I) OR (II) WHERE THE RING IS PHENYL, PIRIDINYL, PIRAZOLILE OR ISOQUINOLINILO; RING B IS FENYL OR HETEROARILE OF 5-6 ELEMENTS; n ES 0, 1 or 2; R2 ES -C (O) -NH- (C1-C6 RENT OPTIONALLY REPLACED WITH HALOGEN, OH OR CN), BETWEEN OTHERS; R3, R4 AND R5 ARE EACH H, CH3, CH2CH3, BETWEEN OTHERS; R6 IS H OR C1-C3 RENT; R1a IS HALOGEN, C1-C6 RENT OPTIONALLY REPLACED WITH HALOGEN, CN OR OH, ALCOXI C1-C6, BETWEEN OTHERS; R1b AND R1c TOGETHER FORM A HETEROCICLOALQUILO OF 3 TO 10 ELEMENTS OPTIONALLY REPLACED WITH C1-C6 RENTAL, BETWEEN OTHERS. ARE PREFERRED COMPOUNDS: 2- [3- (4-ETIL-1H-PIRAZOL-1-IL) -1- [2 - ([1- [2- (4-METHYLPIPERAZIN-1-IL) -2-OXOETIL] - 1H-PIRAZOL-4-IL] AMINO) - [1,2,4] TRIAZOL [1,5-a] PIRIDIN-8-IL] AZETIDIN-3-IL] ACETONITRILE; 2- [3- (4,4- ...

Smart and scalable power inverters

A method and apparatus is disclosed for intelligently inverting DC power from DC sources such as photovoltaic (PV) solar modules to single-phase or three-phase AC power to feed the power grid for electricity generation. A number of smart single-input, dual-input, triple-input, quad-input, and multiple-input power inverters in a mixed variety can easily connect to single, dual, triple, quad, and multiple DC power sources, invert the DC power to AC power, and daisy chain together to generate a total power, which is equal to the summation of the AC power supplied by each smart and scalable power inverter of this invention.